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I. INTRODUCTION
The present work analyzes the interaction between the retinoic acid receptor beta (RARβ) with
the transcription factor AP-1 in the context of HPV-induced carcinogenesis. Before providing
evidence how constitutive RARβ expression abrogatesAP-1 activity in cervical carcinoma cells,
I shall give a brief overview about the individual key regulatory proteins and their function in
normal eukaryotic cells.
1.1 Activator protein 1 (AP-1) transcription factor
1.1.1 General aspects
The transcription factorAP-1 (activator protein 1) is compose of heterogeneous dimeric proteins
consisting of members of Jun, Fos andATF-2 families. Once bound to DNA, the trans-activation
function of a given dimeric complex can vary, which can be explained by differences in
phosphorylation by upstream protein kinases as well as protein/protein interaction with other
cellular factors. As a consequence, distinct sets of genes are targeted, suggesting that individual
members of theAP-1 family have specific functions inAP-1 regulated cellular processes (Angel
et al., 2001).
In vitro, dimers formed by Fos and Jun bind with the highest affinity to an asymmetric
heptanucleotide recognition sequence TGA(C/G)TCA(TRE) and with slightly slower affinity to
a symmetric octanucleotide TGACGTCA(CRE) (Figure 1). The TRE element is found in a wide
range of promoter and enhancer regions embedded in different regulatory contexts. Variation in
recognition sequences may contribute to the differential functions of different Fos-Jun family
dimers at various regulatory elements (Chinenov and Kerppola, 2001).
The repertoire of Fos-Jun proteins in a given cell is subject to changes in response to various
extracellular stimuli. Through dimerization mediated by the leucin zipper, the seven family
members can form 18 different homo and heterodimers. The number of detectable Fos-Jun dimers
varies among different cell types (Chinenov and Kerppola, 2001). Table 1
c-Jun JunB JunD c-Fos FosB Fra-1 Fra-2
c-Jun + + + + + + +
JunB + + + + + +
JunD + + + + +
c-Fos - - - -
FosB - - -
Fra-1 - -
Fra-2 -
Table 1: Dimer combinations of Fos and Jun family proteins capable of forming stable AP-1 transcription factor
complexes.
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The functions of Fos-Jun family proteins depend on the specific cell type in which they are
expressed and are also affected by the specific signals that elicit their expression. Thus, the
functions ofAP-1 must be mediated by mechanisms that depend on the cellular context in which
they are expressed. The mechanisms that give cell specificity include selective dimerization,
interaction with other regulatory proteins and post-translational modifications. Moreover
extracellular stimuli can modulate the abundance of the AP-1 proteins by controlling the
transcription of their genes, the stability of their mRNAs and the activity and stability of the
specific Fos-Jun proteins (Karin et al., 1997; Chinenov and Kerppola, 2001).
1.1.2 AP-1 family members function and regulation
The main components of AP-1 transcription factors can be divided into three major families:
Fos, Jun and ATF.
The Fos family contains the following members, all of them characterized as immediately early
genes because this response occurs in the absence of new protein synthesis:
i. c-Fos: c-fos protein andmRNA are undetectable inmost quiescent cells and require stimu-
lation by hormones, serum mitogens or other ligands to reach easily detectable levels
(Distel and Spiegelman, 1990). Stimulation of the cells induces c-fos transcription very
rapidly and transiently. Several elementsmediate c-fos induction: CRE (cAMPresponse ele-
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ment), SIE (Sis-inducible enhancer) and SRE (Serum response element). SRE is impor-
tant for c-fos induction by a large variety of extracellular stimuli, which lead to extra-
cellular signal-regulated kinase (ERK) activation (Karin et al., 1997). In addition to tran-
scriptional control, the abundance of c-Fos is regulated at the level of mRNA stability.
Adenylate and uridylate-rich elements (AREs), major protein-coding region determinant
of instability (mCDR) and ARE-/mCDR-binding proteins can alter the stability of c-fos
mRNAs.ARE and mCDR elements determine the mRNA turn-over by deadenylation of
the poly(A) tail and nuclease degradation of the mRNA body. In the case of mCDR ele-
ments the process is coupled to translation (Chen et al., 1995; Grosset et al., 2000; Chen
et al., 2002). Finally, the c-Fos content is regulated by protein stability through the
ubiquitin-proteasome pathway, which contributes to determine the duration of the AP-1
response (Tulchinsky, 2000).
ii. FosB: As c-fos, fosB is rapidly and transiently induced after stimulation with serum,
growth factors and phorbol esters but becomes undetectable in 3h (Tulchinsky, 2000).
The fosB gene encodes two funtionally distinct proteins by the production of alternately
spliced transcripts. The long protein FosB, differs from FosB2 by the presence of a C-
terminal extension. FosB is more potent activator of transcription and neoplasic transfor-
mation than FosB2 (Skinner et al., 1997; Herdegen and Waetzig, 2001; Jochum et al.,
2001).
iii. Fra-1/Fra-2: Functional TRE sequences have been described in the promoter of fra-2 and
within the intronic enhancer of fra-1, suggesting that the transcription of both genes can
be regulated via a positive auto-regulatory loop. Fra-1 and Fra-2 lack the C-terminus
trans-activating domain. This combine with the delayed synthesis in response to stimuli,
suggest they might be inhibitory factors which in certain circumstances may limit the
duration of the AP-1 response (Tulchinsky, 2000).
The following members compose the Jun family all of them immediately early genes:
i. c-Jun: The c-jun gene is expressed in many different cell types at low levels and its
expression is enhanced in response to many stimuli via protein kinase C pathway, growth
factors, UV irradiation or cytokines. c-jun is regulated at transcriptional, post-transcrip-
tional and post-translational levels. The c-jun promoter region is highly conserved and
contains potential binding sites for several transcription factors including Sp-1, nuclear
factor-jun, CCAAT transcription factor and AP-1 itself. Induction of c-jun expression is
mediated through a TRE-like site located in the proximal region of the promoter; a c-Jun/
ATF-2 heterodimer rather than a conventional c-Jun/c-FosAP-1 dimer preferentially recog-
nizes this site. Despite its inducible expression, most cell types contain a certain
basal level of c-Jun protein prior to stimulation (Mechta-Grigoriou et al., 2001). It
has been demonstrated that constitutive expression from the c-jun promoter is driven
Introduction 14
by ATF-2 or an ATF-2 dimerization partner distinct from c-Jun under resting condi-
tions (Steinmüller et al., 2001). The phosphorylated form of c-Jun subsequently in-
duces its own transcription through positive auto-regulation (Berry et al., 2001;
Mechta-Grigoriou et al., 2001). c-junmRNA instability maybe mediated by anATTTA
signal sequence in the 3 untranslated region of the mRNA (Vogt and Bos, 1990;
Chen et al., 2002). Additional layer of complexity to the c-Jun regulation is at level
of translation. The c-jun mRNA has a extremely long 5 untranslate region which is
GC rich. Tipically mRNAs with long GC rich 5 untranslate regions are translated
extremely inefficiently, but in the case of c-jun mRNA have been shown that the
translation proceed through internal ribosome entry. The complex folding of the 5
untranslate region creates a structure functionally defined as an internal ribosome
entry segment (IRES). IRES has been implicated as a mechanism to allow translation
of messages under stress conditions in which overall cellular protein synthesis is
compromised (Sehgal et al., 2000). Finally, at protein level c-Jun itself is unstable
having a 90 minutes half-life. It carries a PEST motif which is a sequence involved in
the rapid destruction of short-lived proteins, and is in vivo a substrate for multi-
ubiquitination and proteasome degradation (Musti et al., 1997).
ii. JunB: The sequence analysis of junB promoter reveals several potential regulatory
elements, which include Stat3, CRE, SRE and CAAT enhancer-binding domains.
JunB differs in biological properties from c-Jun and was defined as a negative regu-
lator of cell growth. This functional difference is due to changes in aminoacid se-
quences, which decrease its dimerization potential and eliminate the JNK phospho-
rylation sites, and therefore decrease its trans-activation capacity (Mechta-Grigoriou
et al., 2001).
iii. JunD: In contrast to c-jun and junB, junD is refractory to serum stimulation and its
basal expression remains high in many cell types. The promoter contains several
identified binding sites: CRE, Sp-1, Octamer motif, CAAT-box, a GC-rich region
and AP-1 consensus site. The octamer motif is the major regulator of junD expres-
sion and is specifically recognized by the ubiquitous Oct-1 protein (Mechta-Grigoriou
et al., 2001). There are two predominant JunD isoforms generated by alternative initia-
tion of translation: Full-length (JunD-FL) and a shorter protein (∆JunD) (Short and Pfarr,
2002)
ATF (activating transcription factor) family members:ATF-2,ATF-3 and B-ATF. Unlike Jun and
Fos, expression of ATF-2 is constitutive. The activity of ATF-2 is regulated post-translationally
by phosphorylation after JNK or p38 mitogen-activated protein kinase induction, and it
preferentially interacts with CRE rather than TRE binding sites (Karin et al., 1997; Chinenov
and Kerppola, 2001).
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1.1.3 Modulation of AP-1 function- MAP kinase pathway
AP-1 activation is caused by the increased expression of Fos and Jun proteins after
extracellular stimuli but also by phosphorylation. Fos and Jun are signal converters; they
are activated by external signals, altering transcription of specific genes triggering the cellular
response. The signal is internalized in the cell by a transduction cascade involving the
Mitogen-acivated protein kinases (MAPKs). MAPKs connect cell-surface receptors to critical
regulatory targets within the cell, such as AP-1 family members. They also respond to
chemical and physical stresses, controlling cell survival and adaptation. Mammals express
at least three different regulated groups of MAPKs (see figure 2), extracellular signal-related
kinases ERK1/2, Jun amino-terminal kinases JNK1/2/3, p38 proteins p38α/β/γ and ERK5.
Each MAPK is activated by specific MAPK kinase (MAPKK): MEK1/2 for ERK, MKK3/6
for p38, MKK4/7 for JNK and MEK5 for ERK5. Up-stream each MAPKK can be activated
by more than oneMAPKK kinase, increasing the complexity and diversity of MAPK signaling
(Chang and Karin, 2001). Additionally, in order to generate the appropriate output signal,
MAPK modules have evolved strategies to communicate with other pathways. This cross-
talk can affect signaling properties and information flow and can modify the specificity of
the pathways involved (Schaeffer and Weber, 1999). The duration of the response after
MAPK activation is regulated by MAPK phosphatases (MKPs) which are rapidly induced
by the same stimuli that activate the MAPK pathways (Camps et al., 1999).
MAPK cascades contain at least three protein kinases that work in series and these three
enzymes comprise a module (see Figure 2).
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1.1.3.1 Signaling through extracellular signal-regulated protein kinase (ERK)
pathway
ERK1/2 are among the protein kinases most commonly activated in signal transduction
pathways. They have particularly been linked to cell proliferation, but have important roles in
many other events (English et al., 1999). Activation of the ERK signaling pathway, either by
growth factors or by activating mutations in cytoplasmic effectors such as Ras and Raf, results in
AP-1 activation.
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The Ras cascade is classical ERK activator. There are three ras genes that control cellular
proliferation: Ha-ras, K-ras andN-ras. They encode nearly identical 21 KDa proteins collectively
known as Ras (Marshall, 1995). Ras proteins are positioned at the inner surface of the plasma
membrane where they serve as binary molecular switches to transduce extracellular ligand-
mediated stimuli into the cytoplasm to control signal transduction pathways influencing cell
growth, differentiation and apoptosis. Ras biological activity is controlled by a regulated GDP/
GTP cycle. Single aminoacid substitutions, known as oncogenic activation, at position 12, 13 or
61 unmask Ras transforming potential and create mutant proteins that are insensitive to
stimulation. Consequently, these oncogenic Ras mutant proteins are locked in the active state.
Active Ras forms a high affinity complex with Raf, activating it by a not-fully-understood
mechanism. Raf then phosphorylates and activatesMAPKK-MEK1/2 via direct association with
the catalytic domain. Activated MEKs function as a dual specificity kinases and phosphorylate
MAPK-ERK1/2 to activate them. Once activated, ERK1/2 proteins translocate to the nucleus
where they phosphorylate and activate a variety of substrates that include Elk-1 transcription
factor. This finally leads to the stimulation of the c-fos and other promoters (Campbell et al.,
1998).
1.1.3.2 Signaling through the p38 pathway
The first p38 subgroup member was discovered as a lipopolysaccharide (LPS)induced
tyrosine phosphoprotein and as the target of a drug developed to inhibit LPS-induced tumor
necrosis factor α biosynthesis. Four p38-like MAPKs are known, often activated by cellular
stresses and, as a result, referred to as stress-activated protein kinases. In addition to their roles
in cytokine biosynthesis, they are implicated in many other events (English et al., 1999).
1.1.3.3 Signaling through the Jun N-terminal kinase (JNK) pathway
JNK regulates AP-1 by at least two mechanisms: first, JNK increases expression of Fos
proteins by Elk-1 phosphorylation (Wisdom, 1999). Second, c-Jun activity is post-
translationally up-regulated by JNK-mediated phosphorylation at serines residues within c-
Jun activation domain (Wisdom, 1999). This event increases the trans-activating potential
and DNA binding activity of c-Jun protein. Additionally, phosphorylation increases the
stability of c-Jun, resulting in an increment of its half-life in 2-3-fold in comparison with a
dephosphorylated c-Jun (Musti et al., 1997). Although c-Jun is an exclusive JNK substrate,
JNK can also phosphorylate and activate other transcription factors. ATF-2 is one of them.
It heterodimerizes with c-Jun, stimulating c-jun mRNA expression. Therefore, through
activation of both c-Jun and ATF-2, JNK can regulate the abundance and activity of c-Jun
(Barr and Bogoyevitch, 2001).
Following the exposure of cells to external factors, JNK activation has been routinely measured
by protein kinase activity towards the transcription factor c-Jun. The JNKpathway can be activated
by different stimuli (Figure 3):
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i. Tumor necrosis factor α (TNFα) is a potent activator of JNK signaling and AP-1 (Wis-
dom, 1999). The binding of TNFα to its receptors TNFR1 and TNFR2 generate a cascade
of signals through association with TNF-receptor-associated factors TRAF. The N-termi-
nal effector domain of TRAFs can interact with the MAPKK kinase, MEKK1, and acti-
vate it leading to phosphorylation and activation of the MAPK kinase MKK4/7, which
finally phosphorylates and activates the JNK, resulting in c-Jun phosphorylation at serines
63 and 73. This phosphorylation event consequently activatesAP-1, which in turn induce
genes involved in chronic and acute inflammatory responses. The p38 MAPK pathway
can be also activated by TNFα (Figure 2, Baud and Karin, 2001).
ii. In addition to proinflamatory stimuli, JNK activity is stimulated by certain growth factors. It
has been reported that activation of JNK by serum is dependent onMEKK1 phosphorylation
and activation, because the JNK activation is considerably reduced in Mekk1-/- cells (Xia et
al., 2000).
iii. Ras activation induces JNK phosphorylation and activation through Rac/cdc42 via
MEKK1 leading to c-Jun andATF-2 phosphorylation. Althoug Ha-ras function is essen-
tial for JNK activation by growth factors (but not by cytokines as TNFα), oncogenically
activated Ha-ras leads only to a partial JNK activation (Figure 2, Minden et al., 1995;
Dhanasekaran and Reddy, 1998).
iv. MEKK1 is the key kinase in the pathway of JNK activation. Many stimuli converge on
this kinase resulting in JNK activation. MEKK1 is a serine-threonine kinase which, upon
activation, binds and phosphorylate MKK4/7, which phosphorylates and activates JNK
(Karin, 1995). It has been demonstrated that two threonine residues at the positions 560
and 572 in the sequence ofMEKK1 are essential for catalytic activity.When Thr 560 and
Thr 572 were individually mutated to alanine residues, MEKK1 lost a significant portion
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of its catalytic activity both in terms of autophosphorylation and phosphotransferase ac-
tivity towardMKK4/7 (Siow et al., 1997).Additionally, it has been suggested that the N-
terminal domain of the protein participates in its regulation which explains why a mutant
lacking the amino acids 1-352 exhibit constitutive activation (Minden et al., 1994).
1.1.3.4 Other phosphorylation events that regulate AP-1 activity independent of
MAPK
c-Jun is phosphorylated on 5 to 7 serine and threonine residues. One enzyme that can regulate
c-Jun post-translationally independent of the MAPK pathway is the glycogen synthase kinase-3
(GSK-3). Two serines and one threonine residues were identified as targets of the GSK-3 in
vivo. The residues are located directly upstream of the basic region of the c-Jun protein, the part
of the protein responsible for DNA binding (Figure 4). This close proximity between the
phosphorylation sites and the DNA-binding domain suggest that phosphorylation might alter
DNA-binding. Incubation of bacterially expressed, unphosphorylated, c-Jun protein with GSK-
3 led to a dramatic decrease in its DNA-binding activity (Angel and Karin, 1991).
1.1.4 AP-1 proteins as modulators of neoplastic transformation
Many cytoplasmic transforming proteins, such as Ras, activate AP-1 due to their ability
to activate ERK and JNK signaling pathways. This together with the ability of overexpressed
Fos and Jun proteins to elicit cellular transformation in some systems has provided
circumstantial evidence that AP-1 functions as an important nuclear modulator of
transformation. For example, c-Jun mutant cells are resistant to transformation by activated
Ras and the induction of invasive skin cancers by the combination of an activated Ras transgene
and topical application of phorbol esters is markedly impaired in c-Fos null mice (Wisdom,
1999).
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Additional evidence for the c-Fos role in malignancy progression was obtained from the
determination of theAP-1 composition in tumorigenic and non-tumorigenic human cells. It was
shown that the characteristicAP-1 pattern in HPV-18-positive tumorigenic cells is mainly c-Jun/
c-Fos, while non-tumorigenic HPV-18-positive cells have Fra-1/c-Jun dimers. Stable transfection
with a vector expressing c-Fos in non-tumorigenic HPV-18-positive cells converts them to
tumorigenicity as tested by hetero-transplantation in nude mice (Soto et al., 1999).
1.2 Retinoic acid receptor β
1.2.1 General aspects
Clinical and experimental approaches have shown that vitaminAor retinol, and its biologically
active derivatives or retinoids, exert a variety of profound effects on vertebrate development,
cellular differentiation and homeostasis. These structurally simple molecules (figure 5) can exert
pleiotropic effects through a set of retinoic acid nuclear receptors. The retinoic acid receptors
belonging to the super-family of nuclear ligand-activated transcriptional regulators that include
steroid hormones, thyroid hormone and vitamin D3 receptors. Diversity in the control of gene
expression by retinoid signals is generated through complexity at different levels of the signaling
pathway. The existence of several forms of retinoids, whose synthesis may be cell-specifically
modulated, represents a first level of complexity in the signaling pathways (for review, see
Chambon, 1996).
Two families of nuclear receptors, the retinoic acid receptorsRARs and the rexinoid receptorsRXRs,
each consisting of three isotypes (α/β/γ) encoded in separate genes, have the potential to transduce
the retinoic acid signal in vivo. Isoforms of each RAR also arise in a tissue-related pattern as a result
of differential promoter use and alternative splicing (Napoli, 1996). TheRAR family (RARα, RARβ
and RARγ) is activated both by all-trans retinoic acid (atRA) and by 9-cis retinoic acid (9cRA),
whereas the RXR family (RXRα, RXRβ and RXRγ) is activated exclusively by 9cRA (for review,
see Chambon, 1996).
Purified RARs do not bind efficiently to the retinoic acid response elements (RARE) located
on the promoter regions of genes controlled by retinoids. The purification of proteins that
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stimulate RAR binding led to the demonstration that RXRs form heterodimers with RARs
in solution, and this increases the binding activity. Further analysis suggested that RAR/RXR
heterodimers are the functional units that transduce the retinoid signal in vivo (for review, see
Chambon, 1996).
1.2.2 Structural organization
The structure of retinoic acid nuclear receptors is highly conserved, consisting of six
regions denoted A/B, C, D, E and F (Figure 6) (Mangelsdorf and Evans, 1995). The N-
terminus (region A/B) varies in its size and amino acid sequence and is sometimes lacking.
The DNA-binding domain (DBD) (region C) is highly conserved in its amino acid sequence,
the hinge region D again is variable and the ligand-binding domain (LBD) (region E) is well
conserved. Some nuclear receptors contain a Cterminal domain of unknown function (region
F). Regions C and D participate in DNA binding; region E contains the main nuclear recep-
tor dimerization interface and the ligand-binding function. A ligand-independent activation
function AF-1 has been assigned to the A/B region and the ligand-dependent activation
function AF-2 is located in the C-terminal end of the region E.
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1.2.3 Activation and repression by RAR/RXR
Nuclear receptors can both activate and repress transcription. This results from the ability
of most nuclear receptors to change their conformation by binding to their cognate ligands,
which leads to the formation of different complexes. Retinoic acid receptors can bind to
DNA in their unliganded state and actively repress transcription, whereas when a ligand is
bound, they strongly activate transcription (Figure 7).
i. Ligand-dependent transcriptional activation: Many complexes and cofactors interact
with RARs in a ligand-dependent way (Rosenfeld and Glass, 2001; Lee et al., 2001;
Xu et al., 1999; Torchia et al., 1998). Functional analysis in cells suggest that liganded
RARs activate transcription by the following mechanisms (a) Chromatin remodeling
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by the histone acetyl-transferase activity of cofactors or ATP-dependent chromatin
remodeling machines and (b) pre-initiation complex recruitment or stabilization
(Dilworth and Chambon, 2001).
ii. Ligand-independent transcriptional activation: The ligand-independent activation
function (AF-1) can be induced by phosphorylation, leading to interaction with sev-
eral cofactors in the absence of ligand (Rochette-Egly et al., 1997; Bastien et al.,
2000). Additionally, conformational changes induced by protein-protein contact with
another transcription factor can cause activation of unliganded nuclear receptors (Tolon
et al., 2000).
iii. Nuclear receptor-mediated repression: Unliganded RARs can interact with nuclear
co-repressor complexes such as N-CoR and SMRT (Hörlein et al., 1995; Chen and
Evans, 1995). These proteins contain a highly conserved domain, which is able to
actively repress transcription. The co-repressors interfere with transcriptional acti-
vation by (a) Inhibiting pre-initiation complex formation or similarly locking the
pre-initiation complex into an inactive conformation and (b) deacetylating histone
tails in order to create a hypo-acetylated closed form of chromatin (Laherty et al.,
1998; Heinzel et al., 1997; Alland et al., 1997).
1.2.4 Retinoic acid receptor β isoforms
Three different RARβ isoforms have been described in humans: RARβ1, RARβ2 and
RARβ4 (Figure 8). Each isoform has identical B-F domains (see figure 6); however, the A
domain varies drastically both in size and aminoacid sequence. Two promoters, along with
alternative splicing, produce the different isoforms. RARβ2 and RARβ4 arise from the same
promoter called P2, which contains a strong retinoic acid responsive element (RARE). The
5 untranslated region of the RARβ4 transcript is spliced out including the ATG start codon.
Therefore RARβ4 translation is initiated from an internal CUG codon resulting in an isoform
that lacks all but 4 of the A domain amino acids. In humans, the P1 promoter gives rise to
only one transcript, RARβ1, which appears to be expressed only in fetal tissues (Soprano et
al., 2000). Retinoid treatment induces the expression of RARβ2 and RARβ4 at the
transcriptional level via the RARE element. In contrast, the transcription of RARβ1 is
unaffected by retinoic acid treatment (Mendelsohn et al., 1994). The function or importance
of the different isoforms of RARβ is unknown. Nevertheless a growing body of evidence
supports the hypothesis that retinoic acid receptor β2 is a tumor suppressor gene. RARβ2
expression has been reported to be silenced in many malignant tumors, but molecular
mechanisms are still poorly understood (Yang et al., 2001).
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1.2.5 Retinoic acid receptor β2 and cancer
As was mention RARβ2 can act as tumor suppressor, since loss of its expression is
associated with human tumor progression (Altucci and Gronemeyer, 2001; Hayashi et al.,
2001). RARβ is silenced in various forms of cancer such as breast, oral, lung, esophageal,
gastric, prostata, etc (Qiu et al., 1999; Virmani et al., 2000; Altucci and Gronemeyer, 2001;
Hayashi et al., 2001; Nakayama et al., 2001b; Vourlekis and Szabo, 2003).
In 40% of cervical squamous cell carcinomas, expression of RARβ2 mRNAwas significantly
decreased. The deficiency in the expression of RARβ2 was associated with de novo
methylation of the promoter and the region of the first exon, close to the retinoic acid response
element RARE (Figure 8). It has been proposed that this methylation is an early event during
cervical carcinogenesis (Ivanova et al., 2002).
RARβ2 is the most frequently retinoid receptor lost in different epithelial cancers evaluated
to date, the expression is often lost through epigenetic changes of both maternal and pater-
nal alleles (promoter hyper- and aberrant methylation) and/or loss of heterozigosity on
chromosome 3 combined with epigenetic modification of the remaining allele (Yang et al.,
2001). This event correlates with tumor progression and retinoic acid unresponsiveness.
1.2.6 Retinoic acid receptor β2 re-expression, retinoic acid treatment and tumor
regression
RARβ2 expression can be re-induced in responsive cancer cells by pharmacological treatment
with retinoids. Antisense studies blocking the RARβ2 induction after retinoic treatment reveal that
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the induction of RARβ2 by retinoids may be an early step in the cascade of events leading to growth
inhibition (Sun et al., 2000). Based on this and other findings it has been proposed that the inhibitory
effect of retinoids on cell growth is correlated with the induction of RARβ2 in response to retinoid
treatment.
Likewise, whenRARβ2 is overexpressed in retinoid-insensitive cell lines, the cells acquire retinoid
sensitivity leading to growth arrest (Lee et al., 2000). Moreover, the ectopic overexpression of
RARβ2 in different kinds of cancer induces profound growth inhibition in the absence of additional
retinoid, and increases the retinoid sensitivity. Cells stably expressing RARβ2 demonstrate irre-
versible growth arrest following one week of retinoid treatment (Cheung et al., 1998).
The gene programme(s) regulated byRARβ2 is/are entirely unknown, but is tempting to speculate
that its function might be related to two functionalities that distinguish RARβ2 from the other
receptors: first, RARβ2 interacts only inefficiently with co-repressors, so RARβ2-RXR
heterodimers are more responsive to retinoids than for example RARα-RXR heterodimers.
Second, RARβ2 constitutively represses AP-1, in contrast to the ligand-dependent cross talk of
the other retinoid and rexinoid receptors. It is possible that these activities are unfavorable for
rapid tumor growth (Altucci and Gronemeyer, 2001).
1.2.7 AP-1 trans-repression, the second mode of RARβ2 action
In addition of its function as transcriptional regulator RARβ2 exhibit a secondmode of action
through the cross talk repression based on protein-protein interaction (Figure 9).
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RAR-AP-1 repression is mutual since overexpression of AP-1 components repress the
transcriptional and trans-repressional activity of the RARs (Yang et al., 1997). Conversely, acti-
ve RARs can down regulateAP-1 stimulated transcription, independent of DNA-binding, and is
thus distinct from conventional modes of transcription factor action. It hasbeen demonstrated that
theAP-1 trans-repression accounts for the anti-tumor activity of retinoids.
All three RAR subtypes (α, β, γ), could effectively inhibit the inducedAP-1 activity, and the activity
of the oncogenes c-jun and c-fos onAP-1-containing reporter genes, in the presence of retinoic acid.
However, only RARβ shows a strong retinoic acid-independent inhibition ofAP-1 activity, whereas
inhibition ofAP-1 by RARα and RARγ is retinoic acid dependent. The RARα and RARγ activation
induce RARβ expression, consequently RARβmight function as the main anti-AP-1 retinoic recep-
tor.
Analysis of RARβ protein domains shows that both theN-terminal portion (A/B andCdomains) and
the C-terminal portion (E/F domain) are involved in the inhibition of AP-1 transcriptional activity.
Additionally, theA/Bdomain ofRARβ is responsible for retinoic acid independent repression ofAP-
1 transcriptional activity (Lin et al., 2000). Consequently analysis of RARβ2 and RARβ4 AP-1
trans-repression activity reveal that RARβ4 has not anti-AP-1 activity. Since RARβ4 lacks all but 4
amino acids in its A domain (Figures 6 and 8), these results suggest that the A domain plays an
important role in mediating AP-1 trans-repression activity in the RARβ2 molecule (Soprano et al.,
2000).
1.3 Human Papillomavirus 18 and cervical cancer
1.3.1 Human Papillomavirus
Papillomaviruses are small, non-enveloped icosahedral particles that contain a circular
8Kbp double-stranded DNA, associated with cellular histones. They are a heterogeneous
group of small tumor viruses that infect exclusively epithelial cells. There are more than 85
different fully sequenced genomes (zur Hausen, 1999). Based on their association to benign
or malignant lesions, papillomaviruses are subdivided in low and high-risk groups
respectively. High-risk HPVs can induce immortalization in human keratinocytes in vitro (Dürst
etal., 1987) andhavebeen foundassociatedwithcervical cancer (deVilliers, 1994).Themostprevalent
high-risk HPV type found in cervical cancer is HPV-16 (50-60% of all positive cases) followed by
HPV-18 (10-20%).
The viral genome organization is highly conserved and the can be functionally divided in 3
different regions (Figure 10):
i. Upstream regulatory region (URR): this region contains the origin of DNA replication,
promoter elements driving gene expression and the epithelial-specific transcriptional en-
hancer.
ii. Early region: contains the genes encoding non-structural regulatory proteins responsible
for viral DNA replication (E1/E2), transcriptional self-regulation (E2) and cellular trans-
formation and immortalization (E5, E6 and E7, the viral oncogenes).
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iii. Late region: encodes the structural proteins, required for viral assembly (major capsid
protein L1 and minor capsid protein L2).
HPV enters basal cells at sites of epithelial disruption (Iftner et al., 1992). Once penetrating
basal cells, the virus can persist as a non-integrated episome in a latent state or can induce
benign tumors, papillomas, in a permissive cycle.Alternatively, theHPVgenome can be integrated
into the host genome, disrupting the negative feedback of the E2 protein on theURRand preserving
only the E6/E7 expression. Integration seems to be an early event in the multi-step progression
to cervical cancer (Park et al., 1995), resulting in the up-regulation of HPV expression of
oncogenes E6/E7 and in the increase of the E6/E7 mRNA half-life due to generation of viral-
cellular fusion transcripts (Schwarz et al., 1985; Jeon et al., 1995).
Although E6/E7 expression is sufficient for immortalization of primary human keratinocytes in
vitro (Woodworth et al., 1989;Münger et al., 1989), progression tomalignancy requires further
cellular dysregulation events such as Ras mutations or c-fos overexpression (Medina-Martinez
et al., 1997; Soto et al., 1999). Continuous E6/E7 expression is then required to maintain
the malignant and proliferative phenotype both in vivo and in vitro (Knebel Doeberitz et al.,
1988).
A number of functions have been reported for E6 and E7. E6 binding to the cellular protein
p53 through the E6-associated protein, a protein ligase, targets p53 for ubiquitination and
proteasome degradation. This leads to chromosomal instability with resulting mutational
consequences for HPV-positive cells. E7 binds to retinoblastoma (Rb) and Rb-related proteins
inducing their phosphorylation and enhancing their degradation by ubiquitination. This
releases transcription factors of the E2F family, activating transcription of genes regulating
cell proliferation (for review, see zur Hausen, 2000).
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1.3.2 Cellular control of Human Papillomavirus oncogene transcription
The upstream regulatory region URR is 800-1000bp long and contains the cis-regulatory
elements involved in viral transcription and replication.
Functionally, the HPV-18 URR can be divided in 3 parts:
i. 5-terminal portion of still unknown function, which only marginally contributes to
the activity of the promoter.
ii. Central 230-bp constitutive enhancer essential for the promoter activity.
iii. Promoter proximal region containing basically the promoter region at the 3-termi-
nus of the URR. From this promoter, transcription of both E6/E7 genes is initiated
to give a polycistronic mRNA.
Transcription from the URR is most active in epithelial cells (Hoppe-Seyler and Butz, 1994).
1.3.2.1 Transcription factors interacting with the HPV-18 URR: Role of AP-1
Only one of the factors that interact with the URR is virally-encoded, the others are
cellular transcriptional regulators (Figure 11).
i. Viral E2 protein: Exists in 2 forms, full length behaving as a transcriptional trans-activa-
tor and truncated form responsible for the transcriptional repression. The repression oc-
curs through displacement of transcription factors at the promoter region. Thus E2 may
negatively regulate its own synthesis. After integration this regulation is lost (Bernard
and Apt, 1994).
ii. Nuclear Factor 1 (NF-1): There are three NF-1 binding sites. Mutational analysis of these
in the natural context of the complete URR or in HPV-18 enhancer subfragments up-
stream of a heterologous promoter indicated that they only marginally contribute to tran-
scriptional activation (Hoppe-Seyler and Butz, 1994; Bernard andApt, 1994).
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iii. Octamer-binding transcription factor 1 (Oct-1): The HPV-18 URR contains at least 2 low
affinity binding sites for cellular Oct-1.While the 5-terminal Oct-1 recognition sequence
overlaps with the binding site for the epithelial cell-specific transcription factor KRF-1
(see below), the 3-terminal octamer motif is immediately adjacent to a half palindromic
NF-1 bindingmotif at the 3-border of the constitutive enhancer (Hoppe-Seyler and Butz,
1994; Bernard and Apt, 1994).
iv. Epithelial cell-specific transcription factor 1 (KRF-1): Because this factor is absent in non-
epithelial cells has been hypothesized to contribute to the tissue specificity of the HPV-18
enhancer. Mutational inactivation analyses indicate that the activity of this element can vary
significantly between different epithelial cell types (Hoppe-Seyler and Butz, 1994).
v. Sp-1: This element has been shown to be strictly required for efficient stimulation of the
promoter. Transcriptional activation by Sp-1 is dependent on the functional interplay
with the HPV enhancer elements, as the promoter proximal portion of the URR by itself
is not able to transcriptionally stimulate the homologous or heterologous promoters
(Hoppe-Seyler and Butz, 1994).
vi. Hormone receptors: Glucocorticoid-responsive elements bound by the glucorticoid re-
ceptor or progesterone receptor, mediate transcriptional stimulation. Mutation of this el-
ement results in the complete loss of transcriptional activation by dexamethasone. In the
absence of hormone stimulation the mutation of GRE motif led to a consistent 2-3 fold
up-regulation of the basal activity of the URR (Hoppe-Seyler and Butz, 1994).
vii. Activator Protein 1 (AP-1): There are 2 AP-1 binding sites, one within the constitu-
tive enhancer and one within the promoter proximal region. Mutational inactivation
of these sites in the context of the complete HPV-18 URR leads to an almost com-
plete loss of the transcriptional activity. Indicating that AP-1 plays a key role in the
activation of HPV transcription. Furthermore, mutational analyses indicate that the
integrity of both AP-1 elements within the URR is required for efficient activation of
the promoter (Hoppe-Seyler and Butz, 1994; Bernard and Apt, 1994).
So far it appears that the AP-1 transcription factor is the main regulator determining the
efficiency of HPV expression and in turn in the net amount of the viral onco-proteins E6/
E7. The AP-1 composition differs considerably between immortalize and malignant HPV-
positive cells (Soto et al., 1999). Somatic cell hybridization between different malignant
cervical carcinoma HPV-positive cells established complementation groups on the basis of
AP-1 composition. Intriguingly, non-malignant hybrids revealed an AP-1 composition
characteristically for uninfected normal cells, while malignant somatic cell hybrids still
retained anAP-1 pattern typically for the malignant parental counterparts (Soto et al., 2000).
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1.3.3 Retinoic acid treatment, HPV-18 E6/E7 oncogenes down regulation and growth
inhibition of cervical cancer cells
Defects in the RARβ gene expression may be one pathway leading to the escape from growth
regulation (Si et al., 1996). The stable transfection of RARβ2 in HeLa cells effectively inhibits
cell proliferation and anchorage-independent growth (Si et al., 1996; Geisen et al., 2000).
Additionally, nude mice hetero-tranplantation of this HeLa RARβ clones showed a reduced
tumor growth (Geisen et al., 2000). These experiments demonstrate that, at least in the HeLa
system, RARβ is a growth inhibitor both in vitro and in vivo being the RARβ expression inversely
correlated with the tumor growth potential.
Several retinoic acid-induced effects has been postulated to explain the growth inhibition,
proteolysis of cyclin D1 (Sueoka et al., 1999; Dragnev et al., 2001), reduced expression of
c-myc and increased expression of the cdk inhibitor p27 (Weber et al., 1999; Dimberg et al.,
2001). However, specifically in HPV-positive cervical cancer, the retinoic acid can
transcriptionally repress the HPV-18 E6/E7 promoter and this event correlates with the
negative effect on cell proliferation. Analysis of HPV-18 URR deletions mutants revealed
that the retinoic acid-mediated repression probably occurs via regulatory elements located
in the central enhancer and furthermore a fragment of the HPV-18 central enhancer confers
retinoic acid-dependent repression on the heterologous timidine-kinase promoter (Bartsch
et al., 1992). However, the presence of retinoic acid response elements or retinoic acid
receptor binding sites have not been identified in the HPV-18 URR (MatInspector search
and Blast analysis). Therefore is likely that the inhibition of the HPV-18 E6/E7 expression
is due to interference with other transcription factors bound to this region. It has been shown
that AP-1 is an essential activator of HPV-18 URR bound to the central enhancer and retinoic
acid receptors cause a AP-1 trans-repression. The aim of this work was to reveal whether
exists any relation between the retinoic acid receptor β expression, theAP-1 trans-repression
and the HPV-18 E6/E7 down-regulation.
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Aims of this study
In order to clarify the interplay between retinoic acid receptor β expression, AP-1 activity and
HPV-18 E6/E7 modulation in cervical cancer cells, the following goals were pursued:
i. Identify if retinoic acid treatment induces AP-1 trans-repression.
ii. IfAP-1 is trans-repressed by retinoic acid receptor β, clarify by which mechanisms trans-
repression is mediated.
iii. Identify the mechanism by which retinoic acid negatively regulates HPV-18 E6/E7
expression.
iv. Evaluate if the sole expression of retinoic acid receptor β can leads to HPV-18 E6/E7
down-regulation
v. Find a relation betweenAP-1 induction and HPV-18 E6/E7 expression in cervical carcinoma
cells.
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II. MATERIALS AND METHODS
2.1 Abbreviations
AP-1 Activating protein 1
ATP Adenosin 5-triphosphate
atRA All-trans-retinoic acid
bp Basepair
BSA Bovine serum albumin
CMV Cytomegalovirus
cDNA Complementary DNA from mRNA
DEPC Diethylpyrocarbonat
DNA Deoxyribonucleic acid
dNTP 2-Deoxynucleosine-5-triphosphate
DMEM Dulbeccos modified Eagles medium
DMSO Dimethyl sulfoxide
DTT Dithiothreitol
E-64 N-N-(L-3-trans-carboxyoxirane-2-carbonyl)-L-leucyl-agmatine
ECL-Reagent Enhanced Chemiluminescence Reagent
EDTA Ethylenediaminetetraacetic acid
EGTA Ethylene glycol-bis[β-aminoethylether]-N, N, N, N-tetraacetic acid
EMSA Electrophoresis mobility shift assay
FCS Fetal Calf Serum
Forw Forward
GAPDH Glyceraldehyde-3-phosphate dehydrogenase
HEPES N-2-Hydroxyethylpiperazine-N-2-ethanesulfonic acid
HPV Human papillomavirus
HRP Horse radish peroxidase
IE4/5 Herpes virus enhancer
IgG Immunoglobulin G
IgM Immunoglobulin M
Kbp Kilobasepair
KDa Kilodalton
LB-Medium Luria-Bertoni Medium
M Molar
MEKK1∆ Mitogen-activated protein kinase kinase kinase 1 constituvely active
MG-132 Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal
min Minute
MMP Metalloproteinase
MOPS 3-[N-Morpholino] propanesulfonic acid
mRNA Messenger RNA
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OD Optical density
PAGE Polyacrilamide gel electrophoresis
PBS Phosphate buffered saline
PCR Polymerase chain reaction
Pefabloc SC 4-(2-Aminoethyl)-benzolsulfonylflourid
POH1 Human Pad1 homolog protein
PVDF Polyvinylidene fluoride
RAR α Retinoic acid receptor α
RAR β Retinoic acid receptor β
Rev Reverse
RNA Ribonucleic acid
RNase Ribonuclease
rpm revolution per minute
RSV Rous sarcoma virus
RT Reverse transcription
sec Seconds
SDS Sodium dodecyl sulfate
SDS-PAGE Denaturant polyacrilamide gel electrophoresis
TEMED N, N, N, N-Tetramethylethylendiamine
t-RNA Transference RNA
TNF-α Tumor necrosis factor α
Tris Tris(hydroxymethyl)-aminomethane
v/v Volume percentage
w/v Weight percentage
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2.2 Materials
2.2.1 Plasmids
2.2.2 Antibodies
The promoter for each expression vector is mention in backets
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2.2.3 PCR Primers
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2.2.4 Oligonucleotides for electromobility shift assays, EMSA
2.2.5 Solutions and Buffers
Ampicillin
50 mg/ml in water
Store at 20°C
Biogel-Suspension
1 X TE buffer
5 mM sodium chloride
0.2 %(w/v) SDS
50 %(w/v) Biogel
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Blocking buffer (Western blot)
1 X TBS pH 7.6
5 %(w/v) Milk powder
0.1 %(v/v) Tween 20
Store at 4°C
BSA
1 µg/µl in water for protein
quantification curve Store at 20°C
Buffer A (Cytoplasmic protein extraction)
10 mM HEPES pH 7.9
10 mM Potassium chloride
0.1 mM EDTA pH 8.0
0.1 mM EGTA pH 7.9
Store at 20°C
Before use add proteases and
phosphatases inhibitiors
Buffer C (Nuclear protein extraction)
20 mM HEPES pH 7.5
400 mM Sodium chloride
1 mM EDTA pH 8.0
1 mM EGTA pH 7.9
Store at 20°C
Before use add proteases and
phosphatases inhibitiors
Charcoal stripped fetal calf serum
500 ml fetal calf serum
25 g active charcoal
Mix 30 min at room
temperature
Spin down and sterile filtration
Store at 20°C
Chloroform/Isoamylalcohol (24:1)
24 parts chloroform
1 part isoamyl alcohol
Store light protected at 4°C
Materials & Methods 39
Denaturing solution (Southern blot)
0.5 N sodium hydroxide
1.5 M sodium chloride
Denhardt´s Solution (250X)
5 %(w/v) BSA
5 %(w/v) Ficoll type 400
5 %(w/v) Polyvinylpyrrolidon 25
DEPC Water
0.1 %(v/v) DEPC
1Lwater
DMEM complete
500 ml DMEM
10 % Fetal Calf Serum
100 U/ml Penicillin
100 µg/ml Streptomycin
DNA lysis buffer (3X)
1.5 %(w/v) SDS
150 mM Tris/HCl pH 7.8
150 mM EDTA
DTT
0.1 M stock solution
Prepare fresh
EDTA
0.5 M EDTA pH 8.0
EGTA
0.25 M EGTA pH 7.9
EMSA Binding buffer (5X)
50 % Glycerin
60 mM HEPES pH 7.9
20 mM Tris pH 8.0
300 mM Potassium chloraide
5 mM EDTA
100 µg/ml BSA
Before use add proteases and
phosphatases inhibitors
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E-64
2.5 mg/ml Stock solution
in 50 % ethanol/50 % bidest water
Store at 20°C
Freezing medium (Cell culture)
10 %(v/v) DMSO
30 %(v/v) FCS
60 %(v/v) Medium (DMEM)
Store at 20°C
G-418 (Geneticin sulfate)
375 mg/ml stock solution
in DMEM complete
Store at 20°C
Hybridization solution (Northern and Southern blot)
50 % Formamide
10 U/ml t-RNA
5X SSC
0.1 % Denhardt´s solution
50 mM sodium phosphate buffer pH 6.5
1%(w/v) SDS
Hybridization washing buffer (Northern and Southern blot)
2 X SSC
0.1 % SDS
Laemmli buffer SDS-PAGE (10X)
0.25 M Tris Base
1.9 M Glycine
1 %(w/v) SDS
LB-Medium
10 g sodium chloride
10 g Bacto-Trypton
5 g yeast extract
add Water to 1 liter, pH 7.2
LB-ampicillin plates
LB-Medium
2 %(w/v) Bacto-Agar
Add 50 mg ampicillin per liter
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Luciferase reaction buffer (10X)
250 mMGlycin-glycin
150 mM Magnesium sulfate
pH 7.8 Store at 4°C
Before use dilute to 1X and
add 5 mMATP
Luciferin solution (100X)
10 mg in 1.42 ml of luciferase
reaction buffer
Store light protected at 70°C
Before use prepare a 1X suspension
in reaction buffer
MOPS (20X)
400 mM MOPS
100 mM sodium acetate
20 mM EDTA
pH 7.0 (DEPC water)
Store light protected
Neutralization solution (Southern blot)
1 M Tris pH 7.4
1.5 M sodium chloride
PBS
123 mM sodium chloride
17,6 mM di-sodium hydrogenphosphate-
dihydrate
10 mM potassium dihydrogenphosphate
pH 7.2-7.8
Pefabloc SC
23.8 mg/ml stock solution
Store at 20°C
Poly (dI/dC) Poly (dI/dC)
1 mg/ml (10U=500µg)
in TNE buffer 10 min at 45°C annealing
and cooling at room temperature
Store at 20°C
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RNA loading buffer (2X)
50 % Formamide
2.2 M Formaldehyde
1 %(w/v) Ficoll (type 400)
0.02 %(w/v) Bromophenol blue
1 X MOPS buffer pH 7.0
(DEPC water)
Store at 20°C
RNase A
10 mg/ml RNase A
10 mM Tris pH 7.5
15 mM Sodium chloride
80°C/20 min, store at 20°C
SDS
10 %(w/v) in water
SDS total protein extraction buffer
50 mM Tris pH 6.8
10 % Glycerin
2 %(w/v) SDS
0.74 M 2-Mercaptoethanol
SOC medium 2 % (w/v) Bacto-Trypton
0.5 % (w/v) yeast extract
10 mM NaCl
2.5 mM KCl
10 mM MgCl2
10 mM MgSO4
20 mM Glucose
Sodium fluoride
500 mM Sodium fluoride
Store at 20°C
Sodium ortho-vanadate
10 mM Sodium ortho-vanadate
pH 10 Store at 20°C
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Sodium Phosphate buffer
1 M sodium dihydrogenphosphate (3 parts)
1 M di-sodiumhydrogenphosphate (2 parts)
pH 7.0
SSC (20X)
3 M sodium chloride
0.3 M tri-sodium citrate dihydrate
pH 7.0
TAE (50X)
2 M Tris/HCl
0.25 M sodium acetate
0.05 M EDTA pH 8.0
pH 7.8
TBE (10X)
0.9 M Tris base
0.9 M Boric acid
0.02 M EDTA pH 8.0
TBS (1X)
10 mM Tris/HCl pH 7.5
100 mM sodium chloride
TBST
1 X TBS pH 7.6
0.1 %(v/v) Tween 20
TE (1X)
10 mM Tris-HCl
1 mM EDTA pH 8.0
TNE (1X)
10 mM Tris/HCl pH 8.0
1 mM EDTA
100 mM sodium chloride
TNFα
100 U/µl Stock solution
10 µg in 200 µl bidest water
add DMEM complete to 10 ml
Store at 70°C
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Towbin (1X)
25 mM Tris Base
192 mM Glycine
0.1 %(w/v) SDS
15 %(v/v) Methanol
Trypan blue
0.25 % in PBS
Western blot loading buffer (5X)
10 % SDS
5 mg Bromophenol blue
12.5%(v/v) 2-Mercaptoethanol
5 mM EDTA pH 8.0
50 % Glycerin
300mM Tris pH 6.8
Store at 20°C
2.2.6 Cell lines
HeLa:
Tissue: Adenocarcinoma; cervix.
Morphology: Epithelial
Age stage: 31 years
Ethnicity: Black
Growth properties: Adherent
HPV presence: Type 18 (about 50 copies per cell)
Reference: Boshart et al., 1984; Schwarz et al., 1985
HeLa RARβ clones (β1 and β2):
HeLa cells stably transfected with retinoic acid receptor β2, under the control of the β-actin
promoter, were single cell cloned and expanded. Two of those clones were analyzed in this study
(Geisen et al., 2000).
2.2.7 Chemicals and reagents
[α32 P] dCTP 10 mCi/ml Amersham, Life Science
Acetic acid glacial Merck, Darmstadt
Acrylamide/bis-Acrylamide (29:1), 30% Sigma, Deisenhofen
Active charcoal Serva, Heidelberg
Agarose Invitrogen, Karlsruhe
All-trans-retinoic acid Sigma, Steinheim
Ammonium acetate Fluka BioChemika, Deisenhofen
Ampicillin Roche Diagnostics, Mannheim
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Ammonium persulfate Sigma, Deisenhofen
Bacto-Agar Gibco Life Technologies
Bacto-Tryptone Difco, Detroit
BenchMark (protein marker) Gibco Life Technologies
Biogel P30 BioRad, München
Boric acid Sigma, Deisenhofen
Bovine Serum Albumin Sigma, Deisenhofen
Bradford-Reagent (Bio-Rad ProteinAssay) BioRad, München
Bromophenol Blue Sigma, Deisenhofen
Calcium chloride (dihydrate) Sigma, Deisenhofen
Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal
(MG-132) Calbiochem, Bad Soden
Chloride acid Merck, Darmstadt
Chloroform Merck, Darmstadt
CLONfectin Clontech
Cycloheximide Sigma, Deisenhofen
Diethylpyrocarbonat (DEPC) Sigma, Deisenhofen
Dimethyl sulfoxide (DMSO) Merck, Darmstadt
Dithiothreitol (DTT) Sigma, Deksenhofen
DNAMarkers Gene Ruler 100bp DNA-Ladder MBI Fermentans, Vilnius
DNA 6X loading buffer MBI Fermentans, Vilnius
Dulbeccos modified Eagles Medium (DMEM) Gibco, Eggenstein
E-64 Roche Diagnostics, Mannheim
ECL-Reagent NEN Lifescience Products Inc
EDTA Roche Diagnostics, Mannheim
EGTA Sigma, Deisenhofen
Ethanol absolute Merck, Darmstadt
Ethidium bromide Fluka, BioChemika
Fetal calf serum Gibco Life Technologies
Formaldehyde Merck, Darmstadt
Formamide Fluka BioChemika, Deisenhofen
[γ32 P] dATP 10 mCi/ml Amersham, Life Science
Geneticin (G-418 Sulfate) Calbiochem, Bad Soden
Glycerin Merck, Darmstadt
Glycine Sigma, Deisenhofen
HEPES Gerbu, Gaiberg
Hexanucleotide Amersham-Pharmacia, Freiburg
Hydrochloric acid Merck, Darmstadt
Isoamyl alcohol Merck, Darmstadt
Klenow-Fragment (DNA polymerase I, 5000U/ml) New England Biolabs, Frankfurt
LB-Medium Gibco Life Technologies
Magnesium chloride Merck, Darmstadt
Materials & Methods 46
2-Mercaptoethanol Sigma, Deisenhofen
Methanol Merck, Darmstadt
Milk powder Roth, Karlsruhe
MOPS Gerbu, Gaiberg
Nonidet-P40 Roche Diagnostics, Mannheim
Nucleotides (dNTPs for PCR) Roche Diagnostics, Mannheim
PBS Gibco, Eggenstein
Pefabloc SC Roche Diagnostics, Mannheim
Penicillin 10000U/ml/Streptomycin 10000µg/ml Gibco Life Technologies
Poly (dI-dC) Poly (dI-dC) Amersham-Pharmacia, Freiburg
Potassium acetate Merck, Darmstadt
Potassium chloride Merck, Darmstadt
Potassium hydrogen phosphate Roth, Karlsruhe
Potassium hydroxide Merck, Darmstadt
2-Propanol, Isopropanol Merck, Darmstadt
Random primers Roche Diagnostics, Mannheim
Restriction enzymes Amersham-Pharmacia, Freiburg
RNAse A (90 U/mg) Serva, Heidelberg
Roti-Phenol Roth, Karlsruhe
Sodium acetate Merck, Darmstadt
Sodium azide Sigma, Deisenhofen
Sodium citrate Sigma, Deisenhofen
Sodium chloride Merck, Darmstadt
Sodium dihydrogen phosphate (monohydrate) Merck, Darmstadt
Sodium dodecyl sulfate Sigma, Deisenhofen
Sodium fluoride Merck, Darmstadt
Sodium hydroxide Roth, Karlsruhe
Sodium ortho-vanadate Sigma, Deisenhofen
SuperScript II (Rnase H (-) 200U/µl) Gibco Life Technologies
Taq platinum DNAPolymerase (5U/µl) Invitrogen, Karlsruhe
TEMED Gibco Life Technologies
T4 Polynucleotide kinase (10000U/ml) New England Biolabs, Frankfurt
T4 DNA ligase New England Biolabs, Frankfurt
t-RNA Sigma, Deisenhofen
Tripsin/EDTA Gibco Life Technologies
Triton X-100 Sigma, Deisenhofen
Triton X-100 cell lysis buffer (3X) DB PharMingen, Heidelberg
Trizma-Base Sigma, Deisenhofen
TNF-α Strathmann Biotech, Hannover
Tween 20 Sigma, Deisenhofen
Trypan blue Sigma, Deisenhofen
Urea Merck, Darmstadt
Materials & Methods 47
2.2.8 Laboratory equipment
Analytic Scale AE 160 Mettler, Gießen
Analytic Scale basic Sartorius, Göttingen
Centrifuge 2K15 Sigma, Deisenhofen
Centrifuge Biofuge, Varifuge RF Heraus, Hanau
Developer machine Curix 60 AFGA
Electrophoresis camera Renner GmbH, Dannstadt
Geiger counter LB 1210B Berthold, Wildbad
Gel drier 483 Bio-Rad, München
Hybridization Oven, Hybrid Mini Bachofer, Reutlingen
Incubator (for cells) B5061 EC/CO2, Forma Scientific Heraeus, Hanau
Luminometer, Lumat LB 9501 Berthold
Microscope CK2 Olympus
Minifuge Heraeus, Hanau
Mini-PROTEAN II (minigels western) BioRad, München
Neubauer count chamber Bender and Hobein, Bruchsal
PCR Thermo Cycler MultiCycler PTC-2000 M.J. Research
pH-meter Calimatic 765 Knick
Phosphorimager® Molecular Dynamics,
Sunnyvale, CA
Phosphorimager Cassette Molecular Dynamics,
Sunnyvale, CA
Photometer Ultraspec 3000 Amersham-Pharmacia, Freiburg
Pipette boy acu Integra Biosciences
Pipettes p2.5, p10, p20, p200, p1000 Eppendorf, Hamburg
Power supply EPS 600 Amersham-Pharmacia, Freiburg
Scale 1216 MP Sartorius, Göttingen
Sonifier 250 Branson/Heinemann,
Schwäbisch Gmünd
Sterile Hood (BioGard Hood) Baker Company, Sandford
Thermomixer 5436 Eppendorf, Hamburg
Trans-illuminator 254-366 nm Vetter, Wiesloch
Vortex Heidolf, Rust
Water Bath Julabo, Seelbach
Western blot transfer camera Hoefer, Semiphor Amersham-Pharmacia, Freiburg
2.2.9 Others
Autoradiography cassettes (Kodak) Sigma, Deisenhofen
Cell culture flasks Costar
Cell culture plates Greiner, Nürtingen
Cryo-tubes Greiner, Nürtingen
Eppendorf Tubes Eppendorf, Hamburg
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Films HyperfilmTM ECL Amersham-Pharmacia, Freiburg
Glass pipettes Renner, Darmstadt
Glass wool Serva, Heidelberg
Nylon membranes (GeneScreen PlusTM) NEN Lifescience Products Inc
Paper filters Schleicher and Schüll, Dassel
Pipet Tips (Sterile) Becton and Dickinson, Heidelberg
Pipet Tips Greiner, Nürtingen
Photometer plastic Cuvettes Greiner, Nürtingen
Polypropilene conical tubes Falcon, Becton-Dickinson
PVDF-membranes (Immobilon P) Millipore, Eschborn
Sterile filters Millipore, Eschborn
X-ray films Fuji
Whatman 3MM paper filter Schleicher and Schüll, Dassel
2.2.10 Kits
Absolutely RNATM RT-PCRMiniprep kit Stratagene
EffecteneTM transfection Reagent Qiagen, Hilden
Hexalabel PlusTM DNA Labeling kit MBI Fermentans, Vilnius
High Sensitivity β-galactosidase Assay kit Stratagene
One shot® TOP 10 Invitrogen
Plasmid Purification kit Qiagen, Hilden
Qiaquick Gel Extraction kit Qiagen, Hilden
SAPK/JNKAssay kit Cell Signaling Tech.
2.3 Methods
2.3.1 DNA probes preparation
2.3.1.1 Competent bacteria transformation (Dagert and Ehrlich, 1979)
Commercially available One-shot® TOP 10 competent cells were thawed on ice, 2ng of
DNA were added, mixed, and incubated for 30 minutes on ice. Later, cells were incubated at
42°C for 30 seconds and chilled on ice for 2 minutes. The cells were diluted l:5 in pre-warmed
SOC-Medium and incubated for 1 hr at 37°C under constant shaking. Twenty and two hundred
microliters of the transformed cells were plated on LB-ampicillin plates and incubated at 37°C
overnight. Next day, an individual colony was picked, transferred to 10ml ampicillin-containing
LB-medium and incubated for about 8h at 37°C.
After the incubation 800µl of this bacterial suspension were mixed with 200µl of 87% glycerin-
sterile solution, transfer into cryo-tubes and frozen at -70°C for its posterior use. In order to
obtain quantitative amounts of plasmids, the QIAGEN maxiprep kit was used following the
attached instruction manual. The concentration of DNA was determined photometrically by
measuring the optical density (OD) at 260/280 nm. 1 OD unit corresponds to 50µg DNA/ml.
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2.3.1.2 Plasmid-DNA restriction analysis
See sections 2.3.4.3DNArestriction analysis and2.3.4.4DNAelectrophoresis andSouthern blot
2.3.1.3 DNA extraction from agarose gel QIAquick gel extraction kit
DNA fragments were extracted from agarose gels using the QIAquick gel extraction kit
(Qiagen). The protocol allows the extraction of DNAfragments in size ranges between 100 bp to
10Kbp.After agarose gel electrophoresis the DNAfragment was cut out from the gel, transferred
into an eppendorf tube and subsequently treated exactly as described in the attached instruction
manual.
2.3.2 Techniques of cell culture
2.3.2.1 Cell culture
Cervical carcinoma cell line HeLa and HeLa clones stably transfected with pbact-RARβ
(Geisen et al., 2000) were maintained in Dulbeccos modified Eagles medium (DMEM),
supplemented with 10% FCS, 100U/ml penicillin and 100µg/ml streptomycin.
In order to keep the selection pressure the clones were grown in a media containing 750µg/ml of
G-418. Incubation was carried out at 37°C with 5% CO2 and 95% humidity.
The cell cultures that reached the sub-confluent growth (80-90% confluency) were washed once
with PBS and treated with Trypsin/EDTA at 37°C until the cells were removed from the plate.
The trypsinization was stopped with the addition of complete DMEM and the cells were dilute
between 1/5 to 1/30 in new medium depending on the future necessities.
2.3.2.2 Thaw and freeze down eukaryotic cells
To defrost cells the cryo-vials were warmed up to 37°C, once de-frozen the cell-containing
medium was transfer to a conical tube and diluted in DMEM complete medium 1:10. The cells
were spinning down during 5min at 2000rpm (Varifuge RF, Heraus), 4°C. Then the pellet was
re-suspended in a fresh medium and transferred to a culture flask or plate for incubation at 37°C
with 5% CO2 and 95% humidity.
For freeze down sub-confluent culture plates (80-90% confluency) were trypsinized as in the
section 2.3.2.1. The cells were centrifugated 5min at 2000rpm (Varifuge RF, Heraus), 4°C and
the pellet was re-suspended in freezing medium. The cell suspension was placed in cryo-vials
(app. 106 cells/ml/vial) and cooled down to 70°C. Later the cryo-vials containing cells were
transferred to the liquid nitrogen to long term conservation.
2.3.2.3 Cell counting
In order to determine the cell concentration (cells/ml) was used the trypan blue dye, which
additionally allow to determine the living cells. After trypsinization the cells suspension was
transferred to a conical tube. A certain volume of cells suspension was mixed with the trypan
blue dye solution 1:1 and counted in a Neubauer chamber.
The number of cells was calculated as:
Cells/ml= # cells counted x104 xDilution factor
# squares counted
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2.3.2.4 Cell treatment with retinoic acid, MG-132 and TNFα
i. For retinoic treatment, cells were incubated with 10µM all-trans-retinoic acid (atRA)
disolved in dimethylsulfoxide (DMSO) as a 10-2M stock solution and kept at 20°C light
protected. Four hours before treatment with atRA, the normal culture media was replaced
by media containing 10% charcoal-stripped serum in order to reduce the retinoids level
present in cell culture medium. The cells were exposed to atRA for 72 h without change
of culture media, adding fresh atRA after 48h incubation.
ii. Confluent cells were treated with 20µM of MG-132 dissolved in DMSO during 8h.
The stock solution was prepared at 20mM and stored at 20°C.
The final concentration of the solvent DMSO in the culture media was 0.1% (v/v), the
control cultures received media containing 0.1% (v/v) DMSO alone and were incubated
at the corresponding experimental conditions.
iii. TNFα was resuspended in DMEM complete medium as 100U/µl stock solution and
store at 70°C. Confluent cells were treated with 500U/ml during 15 or 30 minutes.
Between 15-30 minutes is detected the maximal JNK activation and after 30 minutes is
possible to observed the c-Jun phosphorylation.
2.3.3 Protein analysis
2.3.3.1 Nuclear and cytoplasm protein preparation (Schreiber et al., 1989)
Nuclear extracts were prepared using the method of Schreiber et al. 1989 with the only
modification that phosphatases inhibitors and proteases inhibitors were included in the buffers
A and C at concentrations suggested by the manufacturer.
Stock Activity Final concentration
0.1M DTT 1mM
23.8mg/ml(in H2O) Pefabloc SC Serine-proteases inhibitor 0.5mg/ml
2.5µg/ml(in H2O) E-64 Cysteine-protease inhibitor 5µg/ml
0.5M NaF Phosphatase inhibitor 1mM
10mM Na3VO4 Phosphatase inhibitor 0.2mM
For the nuclear-cytoplasm protein extraction a 60cm2-culture plate with 90-100% confluence (app.
3x106 cells) was washed twice with isotonic PBS. Then 1.6ml of the hypothonic bufferAwas added
and the cells were scrapped. The cells suspension was placed into an eppendorf tube and ice-cooled
15min to allowcell swelling. Subsequently, 100µl of the10%solutionof non-ionicdetergentNonident
P-40 were added to the cells suspension and the eppendorf were vortex 10sec to get the plasma
membrane lysis.After centrifugation at 14000rpm, 1min, 4°C the supernatant contain the cytoplasmic
protein and the pellet the intact nuclei, which kept the nuclear protein inside.
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The cytoplasm protein-containing extract was alicuoted and stored at 70°C. In this extracts
the protein concentration was determined by the Bio-Rad DC (Detergent Compatible) protein
assay based on a modified Lowry method (Lowry, 1951). For each sample 2-4µl of
cytoplasmic protein extract was diluted in 200µl of bi-destilated water, next 100µl of the
reagent A* (1ml Reagent A plus 20µl Reagent C) and 800µl of Reagent B were added,
mixed and incubated 15min at room temperature. Finally, the absorbancy of the samples was
photometrically measured at 750nm and the concentration was determined using a standard
BSA curve as reference.
The nuclei-containing pellet was re-suspended in 200µl of ice-cooled buffer C and placed 15min
on ice mixing it every 2min. Finally, the extract was centrifugated at 14000rpm, 5min, 4°C and
the nuclear protein containing-supernatant was alicuoted and stored at 70°C. The protein
concentration of the nuclear extracts was determined by Biorad Bradford-Method (Bradford,
1976). Two to five microliters of the nuclear protein preparation was diluted in 800µl of bi-
destilated water and 200µl of the Biorad reagent was added. After gently mix the absorbancy
was measured at 595nm and the protein concentration was determined using defined amounts of
BSA as standard.
2.3.3.2 SDS-total protein extract (Klotz et al., 1999)
To prepare SDS-total protein extracts, cells were washed twice with cold PBS, 500µl of
PBS was added and the cells were scrapped, transferred to an eppendorf tube and centrifugated
for 30sec at 13000rpm. The pellet was lysed in SDS-total protein extraction buffer without 2-
mercaptoethanol. The lysate was sonified twice 15sec (50% power capacity, position 5) at 4°C.
Subsequently, the extract was boiled 5min and later ice-cooled. The protein total extract was
divided in 2 aliquots, one without 2-mercaptoethanol for protein quantification and the other
was supplemented with 0.74M 2-mercaptoethanol, both were stored at -70°C.
Protein concentration was determined by the Bio-Rad DC (Detergent Compatible) protein assay
section 2.3.3.1.
2.3.3.3 SDS-Polyacrylamide gel electrophoresis (Laemmli, 1970; Hames and Rickwood,
1990)
This system is based on a discontinuous gel in which the stacking and separating gel
layers differ in salt concentration, pH and acrylamide concentration.
Depending on the size of the protein 10% to 12% acrylamide gels were used, the separating
gel contains 0.4M Tris pH 8.8, 0.1% SDS, 10-12%Acrylamide/Bis-acrylamide (29:1), 0.5%
ammonium persulfate and 0.07% TEMED. After 1h of polymerization at room temperature,
a 3% stacking gel solution was added, the stacking gel contains 0.125M Tris pH 6.8, 0.1%
SDS, 3% Acrylamide/Bis-acrylamide (29:1), 0.5% ammonium persulfate and 0.16 % TE-
MED.
Between 25-50µg of total protein were mixed with Western loading buffer, heated at
95°C for 5min and loaded in the gel. The run was performed in Laemmlis running buffer
and the running time was approximately 2h (15mA until dye front reached separating gel,
then 30mA).
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2.3.3.4Western blot Semidry (Gallagher et al., 1997)
The proteins were transferred from the gel to the polyvinylidene fluoride PVDF-membranes
using a semidry blotting system.After electrophoresis the transfer stackwas assembly: over the semi-
dry blotter were placed 9 sheets of whatman 3MM filter paper cut to the gel dimensions and soaked
in Towbin buffer, on them the pre-activated membrane and on top the gel followed by other 9
sheets ofwhatman 3MMpaper soaked in Towbin buffer.The transfer proceeded at 0.8-1.2mA/cm2
at 4°C for 70min, depending on the protein size.
Then PVDF-membrane was incubated 1 hour at room temperature in Blocking solution,
and subsequently incubated overnight at 4°C with the first antibody (diluted in blocking
solution or BSA following the manufacturer recommendations). Next day, the membrane
was washed five times with TBST 5min each, followed by the incubation with the secondary
antibody in blocking solution for 1h at room temperature. Finally, the membrane was washed
again as before, incubated 2min with the ECL reagents and exposed on HyperfilmTM ECL
films.
In order to use the same filter for re-incubation with additional antibodies, membranes were
stripped in 200mM NaOH for 5min and washed with water and TBS. Then were ready to
block again and repeat the process with the selected antibodies.
2.3.3.5 Kinase assay: SAPK/JNK assay kit (Figure 12)
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JNK activity was assayed using the SAPK/JNK assay kit (Cell Signalling Technology)
following the manufacturer instructions. Cells treated for 15min with TNFα, 8h with
proteasome inhibitor MG-132 or 24h post-transfected with MEKK1∆ were harvested in 1X
cell lysis buffer and JNK and phospho-JNK were pull down from the extracts (250µg total
protein kinase extracts) using 2µg of c-Jun fusion protein beads. Then pellets were incubated
in 1X kinase buffer supplemented with 100µM ATP at 30°C for 30 min. SDS-PAGE and
immuno-blot allowed the detection of c-Jun phosphorylation. The controls were un-treated
or un-transfected cell extracts. Is important to note that the c-Jun fusion protein is a
recombinant protein fusion of c-Jun codons 1-89 and glutathione S-transferase and has a
reduced molecular weight (33-35KDa) in comparison to c-Jun cellular protein (40KDa).
2.3.4 Nucleic acids analysis
2.3.4.1 RNA-extraction Absolutely RNATM RT-PCR Miniprep kit
RNA was isolated with the Absolutely RNATM RT-PCR miniprep kit (Stratagene)
according to manufacturer instructions. For the RNA extraction a 60cm2-culture plate with
90-100% confluence (app. 3x106 cells) was washed twice with isotonic PBS, 500µl of PBS
was added and the cells were scrapped and transferred to an eppendorf tube. Cells suspension
was spinning down at 3000rpm (Varifuge RF, Heraus), room temperature, 5min. The cells
pellet was re-suspended in 600µl of Lysis buffer supplemented with 4.2µl of 2-
mercaptoethanol and vortex repeatedly to ensure that the viscosity of the lysate was low.
Afterwards, the lysate was filter and mixed with 70% DEPC-ethanol. The filtrate was
transferred to a Fiber-Matrix Spin Cup in order to allow binding of the nucleic acids to the
matrix. The matrix was washed with low salt washing buffer once and then the DNase
treatment proceeded. Next, the matrix was washed once with high salt buffer and twice with
low salt buffer and the pure RNA was eluted from the matrix with TE pH 7.5 at 60°C. The
concentration of RNA was determined photometrically by measuring the optical density
(OD) at 260/280 nm. 1 OD unit corresponds to 40mg RNA/ml.
To check RNA quality, approximately 5µg of RNAwas separated on 1% agarose/1X MOPS
gel in presence of ethidium bromide under non-denaturing conditions section 2.3.4.5.
2.3.4.2 DNA extraction from eukaryotic cells
Cells were washed twice with PBS, incubated with 3ml DNA lysis buffer for 10min at
room temperature, scrapped and transferred into 15ml falcon tubes. Proteinase K was added at
final concentration of 200ng/µl and incubated at 56°C for 1 hr. Nucleic acid were purified using
phenol/chloroform extraction. After centrifugation, the upper DNA-containing aqueous phase
was transferred into a new tube where DNAwas precipitated after addition of ammonium acetate
(2M final concentration) and 0.8 volumes of isopropanol. The mixture was centrifuged and the
pellet was washed twice with 70% ethanol, air-dried and resuspended in TE buffer. The
concentration of DNAwas determined photometrically bymeasuring the optical density (OD) at
260/280 nm. 1 OD unit corresponds to 50mg DNA/ml. DNA was treated with RNAseA
(Ribonuclease A, 10µg/ml) during 10 minutes at 37°C.
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2.3.4.3 DNA restriction analysis
For restriction analysis, 1µg of DNA was supplemented with 2U of restriction enzyme in
the corresponding buffer as recommended by the manufacturer.After 2 hours at 37°C, DNAwas
loaded in agarose gels.
2.3.4.4 DNA electrophoresis and Southern blot
Agarose gel electrophoresis is a standard method to separate, identify and purify nucleic
acid fragments. The concentration of agarose used for the gel depends on the size of the
DNA fragments to be analyzed. By using the fluorescent intercalating dye ethidium bromide
at a final concentration of 0.5µg/ml the visualization of the nucleic acids within the gel is
possible.
The required amount of agarose was added to the appropriated amount of TAE1X buffer
and the mixture was heated to allow all the agarose to dissolve. The solution was cooled
down and then was added 0.5µg/ml of ethidium bromide. The gel was poured and allowed
to solidify. The gel was transferred to an electrophoresis chamber filled with TAE1X buffer
and the samples were loaded after being mixed with agarose loading buffer (6:1). The
electrophoresis proceeded between 2 to 8 V/cm. Later, the gel was place on an UV trans-
illuminator and photographed.
After DNA restriction and electrophoresis, the agarose/1X TAE gel was incubated for 45min
in denaturing solution.
Figure 13: Assembly for nucleic acids transference.
For blotting, a pack of high absorbent paper was used and 4 pieces of 3MM paper were
placed on it (first 2 papers dry and then 2 papers wet after soaking in denaturing-solution).
Gene Screen nylon membrane, previously incubated 1min in bi-destilate water and 15min
in denaturing-solution, was placed on the 3MM wet paper. Finally, the agarose gel was laid
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on the nylon membrane (see Figure 13). The whole assembly was then covered with plastic
paper and left overnight at room temperature. Next day, the nylon membrane was washed 15
minutes in neutralization solution and air-dried over 3MM paper. The membrane was
then ready for hybridization.
2.3.4.5 RNA electrophoresis and Northern blot (Alwine et al 1977)
RNAwas separated in 1% agarose/1XMOPS/ethidium bromide gels under non-denaturing
conditions. One volume of RNA-loading buffer was added to each probe, heated 10min at 65°C
and ice cooled 3min before loading. The gel was run at 60V for 2h and then photographed.
After electrophoresis the gel was incubated for 15 min in 20X SSC buffer. For blotting, a pack of
high absorbent paper was used and 4 pieces 3MM paper were placed on it (first 2 papers dry and
then 2 papers wet by soaking in 20X SSC buffer). Gene Screen nylon membrane previously
incubated 1min in bi-destilated water and 15min in 20X SCC was laid on the 3MM paper.
Finally, the agarose gel was deposited over the nylon membrane and the whole assembly was
wrapped with plastic paper (see also Figure 13). RNA transfer proceeded over night at room
temperature. Next day, the nylon membrane was washed for 5 minutes in 2X SSC and air-dried
over 3MM paper. After this step, the membrane was ready for hybridization.
2.3.4.6 Probe labeling Random-Priming (Feinberg and Vogelstein, 1983) and
Hybridization (Southern, 1975)
The radioactive probes for hybridization analysis were obtained by random priming, in
which a mixture of random hexamers is used to prime DNA synthesis in vitro from a linear
denaturated DNA template. For this purpose the HexalabelTM DNA labeling kit was used.
Briefly, 100ng DNAwere diluted in 1X reaction buffer, boiled 10min and cooled down on ice.
Later, the appropriated nucleotides mix (-dCTP), 25 µCi/µl α32P-dCTP and 5U of Klenow-
polymerase were added. The reaction was incubated for 30min at 37°C, then a complete dNTPmix
was added and the incubation was prolonged 5min. Subsequently, the unincorporated label was re-
moved by filtration of the TNE-diluted labeling reaction through a Biogel-suspension column.
Blot pre-hybridization was performed in hybridization buffer for at least 1h at 42°C, after that
denaturated radioactive probe was added to the pre-hybridized membrane and hybridization
proceeded over night. Next day, filters were washed twice with hybridization washing buffer
at 68°C and exposed on HyperfilmTM ECL films at 70°C.
2.3.4.7 Reverse transcription and polimerase chain reaction: Semi-quantitative RT-
PCR
cDNA was obtained from one to five micrograms of RNA by using random primers and
SuperScript II reverse transcriptase following the manufacturer instructions. The random
primers and the RNA were heated at 70°C for 10min and chilled on ice. Then the mixture
was supplemented with 1X reverse transcription (RT) buffer (50mMTris-HCl pH 8.3, 75mM
KCl, 3mM MgCl2), 10mM DTT, 500µΜ dNTPs and incubated at 25°C for 10min for the
annealing step. After annealing, 100U of reverse transcriptase SuperScript II was added and
the reaction was incubated 50min at 42°C for the first cDNA strand synthesis. Finally, the
cDNA was heated to 70°C for 15min and chilled on ice.
Materials & Methods 56
PCRs were performed in 50µl final volume containing 10mM Tris-HCl pH 8.3, 200µM
dNTPs mix, 500nM of each primer, 5U of Taq platinum polymerase and 1-5µl of cDNA.All
PCR reactions were performed for 35 cycles consisting of 30sec at 94°C, 45sec at the
corresponding annealing temperature and 30sec at 72°C, with a final extension of 10min.
The amount of cDNA and the number of cycles were carefully standarized in order to reach
a semi-quantitative indication of the RNA content. The PCR products were analysed in 1-
2% agarose gels.
2.3.5 Protein-DNA interaction
2.3.5.1 Electrophoresis mobility shift assay (EMSA)
The electrophoresis mobility shift assay, EMSAdetermines the binding interaction between
DNA and DNA-binding proteins, such as the interaction of transcription factors with the
corresponding regulatory regions. The complexes of protein and DNA migrate more slowly
through a non-denaturating polyacrilamide gel than unbound double-stranded oligonucleotides.
The addition of antibodies to the reaction is commonly used to determine the identity and
specificity of the binding protein. If the antibody recognise the DNA-protein complex, it can
bind and retard even more the migration of the complex in the gel (Figure 14).
The oligonucleotides used in gel retardation assays were made in anApplied Biosystems (Foster
City, CA) synthesizer using phosphoramitide chemistry and they were further purified by HPLC.
For electrophoretic mobility shift assays 2µg of each oligonucleotide strand (sense and anti-
sense) was annealed in TNE by a PCR program that include 10min at 85°C followed by a
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temperature decreased of 0.5°C every 30sec. Two hundred nanograms of annealed
oligonucleotides were labelledwith 32P-γ-ATP(Amersham, 3000Ci/mmol) andT4 polynucleotide
kinase at 37°C, 30min. Non-incorporated label was removed from the labeled oligonucleotides by
gel-purification in a 15% polyacrylamid/1X TBE electrophoresis at room temperature. The labelled
oligonucleotides were extracted from the polyacrilamide in TNE by shaking over night at 4°C.
Binding assay was performed in a 20µl reaction volume containing 1X EMSA binding bu-
ffer, 2µg poly(dI-dC) poly (dI-dC) and 2µg nuclear extract. After 5min at room temperature,
10000 cpm of 32P-γ-ATP 5-end labelled double-stranded oligonucleotide probe was added.
Reaction was incubated for additional 30 min at room temperature.
For super-shift analysis 2µg of the specific antibody was added after the 30min at room
temperature and the reaction was further incubated for 1h at 4°C.
DNA-protein complexes were resolved in a 5.5% non-denaturing polyacrylamide gel (29:1),
dried and exposed overnight in Fuji medical X-ray films.
Bands were quantified with a Molecular Dynamics (Sunnyvale, CA) Phosphorimager using
the Image Quant program as software.
2.3.6 Transient transfection analyisis
2.3.6.1 Transient transfection protocol Effectene
Transient transfection experimentswere used to analyse the effect of some proteins expression
over the RARβ-AP-1 trans-repression phenomenon or to monitor the AP-1 or RARβ activity
under certain conditions.
The transfection experiments were simple, double or triple depending on how many plasmids
were introduced into the cells and in all cases the transfection was carried out with EffecteneTM
reagent following the manufacturer instructions. For simple transfections 2.5x106 cells were
plated in 60-cm2 dishes the day before transfection. Next day, 2µg of the plasmid DNA was
mixedwith 300µl of DNA-condensation buffer, 16µl of enhancer and 60µl of effectene, following
the incubation time recommended to allow the complexes formation, 3ml of complete DMEM
was added and the transfection complexes were poured into the cells. Cells were incubated over
night in the presence of the pDNA-transfection-complexes and then were splited in two or three
21-cm2 plates in order to prepare RNA, total-protein extracts and nuclear-cytoplasm extracts.
In the case of double transfections 2.5x106 cells were plated in 60-cm2 dishes. Next day, cells
were co-transfectedwith 1.5µg of plasmidDNA (TRE-Luciferase, Promega or RARE-Luciferase
D1 (Bartsch et al., 1992)) and 0.5µg of SV-40-β-galactosidase as control for transfection, using
the same protocol as described for simple transfections.
One day after transfection, cells were splited in two plates (for luciferase andβ-galactosidase extract
preparation) andbetween12-24h later cellswere treatedwithMG-132 (8h) or atRA(4h) usingDMSO
as control.Cellswereharvested andLuciferase activitywasmeasuredusing a luciferase assay (section
2.3.6.2). Data were normalized to the co-expressed β-galactosidase activity (section 2.3.6.3).
In the case of the antisenseFra-1 expression plasmid transfection 1.5µgof the antisenseFra-1 plasmid
were co-transfectedwith 0.5µg ofMEKK1∆ expression plasmid, using the same number of cells and
the same transfection conditions as before. One day later, cells were splited in two plates in order to
prepare RNA and nuclear-cytoplasm extracts.
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Finally for the triple transfection, 2µg of the MEKK1∆ or Ha-ras-mutant expression plasmid
were co-transfected with 1.5µg of TRE-Luciferase (Promega) and 0.5µg of SV-40-β-
galactosidase. The DNAwas mixed with 600µl of DNA-condensation buffer, 32µl of enhancer
and 120µl of effectene. Following the incubation time recommended to allow the complexes
formation, 3ml of complete DMEM was added and the transfection complexes were applied
to 2.5x106 cells plated in 60-cm2 dishes. Cells were incubated over night in the presence of
the pDNA-transfection-complexes and then were splited in two plates for luciferase and β-
galactosidase extract preparation. Luciferase activity was measured using a luciferase assay
(section 2.3.6.2). Data were normalized to the co-expressed β-galactosidase activity (section
2.3.6.3).
For the Effectene protocol the transfection efficiency in HeLa cells was higher than 30% as
determined by transfection with expression vector carring the green fluorescence protein.
2.3.6.2 Firefly luciferase reporter gene analysis
After the specific transfection conditions and/or treatments, cells were washed twice with
cold PBS and 500µl of Triton X-100 cell lysis buffer 1X was added. Cells were incubated
15min on ice and then 5min at room temperature, afterwards cells were scrapped and transferred
to an eppendorf tube. The cell lysates were centrifugated 10sec and the clarified extracts were
transferred to a fresh eppendorf, frozen down on dry ice and then stored at 70°C.
For the luciferase assay 350µl of the 1X luciferase reaction buffer was mixed with 50-100µl of
the sample and immediately placed into the luminometer where automatically was injected 100µl
of 1X luciferin solution.
Luciferase activity was calculated in RLU/mg of protein and normalized according to the β-
galactosidase specific activity (section 2.3.6.3). The fold induction was calculated with respect
the normalized luciferase activity of the specific controls in each transfection case.
2.3.6.3 β-galactosidase normalization High-Sensitivity β-Galactosidase assay kit
After the specific transfection conditions and/or treatments, cells were washed once with
PBS and 500µl of lysis buffer was added. Cells were frozen at 20°C for 30min and later thawed
at room temperature to allow the lysis. The cell lysate was transferred to an eppendorf tube and
centrifugated at 12000rpm, 5min, 4°C. The supernatants were collected and placed in a new
tube and stored at 20°C.
For the analysis 100µl of the cell extract was mixed with 900µl of the substrate chlorophenol
red-β-D-galactopyranoside (CPRG) 1X, vortex 5min and incubated at 37°C in a water bath until
the sample became red. The reaction was stopped by the addition of 500µl of stop solution. The
time spent in the process since CPRG addition until stop solution addition was recorded. The
optical density of the samples wasmeasured at 570nm, and the specific activity of β-galactosidase
was calculated as indicated by the manufacturer:
Concentration of chlorophenol red (nmol/ml)= OD x 55 (A)
Amount of chlorophenol red (nmol)= (A) x 1.5ml (reaction volume) (B)
Activity of β-gal (nmol/min or U)= (B)/incubation time at 37°C (min) (C)
Specific activity β-gal (U/mg)= [(C)/protein concentration of the lysate (mg/ml)]/0.1ml (vol-
ume of lysate used in the assay)
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2.3.7 Retroviral vector construction
2.3.7.1 Cloning of Fra-1 cDNA on pLXIN vector
The Fra-1 insert was excised from the pSG-Fra-1 plasmid by restriction digestion with
HincII-EheI and gel purified. Simultaneously the bicistronic retroviral vector pLXIN (Invitrogen)
was digested with HpaI in order to open the plasmid generating blunt ends.After gel purification
of the digested plasmid, the vector was de-phosphorylated to avoid the re-circularization and the
blunt ligation reaction proceeded in a 10:1 insert:vector ratio at 16°C over night.
One-shot® TOP 10 chemically competent cells were transformed with 1-5µl of the ligation
reaction and plated in LB-Ampicilline (section 2.3.1.1). Resistant colonies were picked up and
grown, plasmid DNA mini-preparations were carried out using the QIAGEN miniprep kit
following the attached instructionmanual and restriction analysis of the plasmids was performed
using the restriction enzymes EcoRI which excise the insert andApaI which determine the insert
orientation (sense or antisense). In order to re-confirm the fra-1 cloning, a Southern blot of the
digested plasmids was performed and hybridized with fra-1 probe.
2.3.7.2 Transfection of the virus producing cell line RetroPackTM PT67
(Figure 15)
All security rules were followed to avoid any biological contamination in the working
area.
The Clontech RetroPackTM PT67 cell line is a mouse fibroblast (NIH 3T3)-derived cell line
designed for stably producing high-titer retrovirus. Virus produced by RetroPack PT67 cells
express a dualtropic envelope, 10A1, that can infect mouse, rat, human, hamster, mink, cat, dog
and monkey cells. Virus produced by these cells can enter target cells via two surface molecules,
the amphotropic retrovirus receptor, RAM1 and the GALV receptor. That means if one receptor
is not abundantly expressed by a given species or cell type, the alternative receptor may still
allow viral entry. Thus virus packaged by RetroPack 67 has a broad mammalian host range.
The RetroPack PT67 cell line was thawed and grown in high glucose DMEM medium. A kill
curve for G-418 was performed in order to determine the antibiotic concentration and the time
necessary for isolation of resistant transfected virus-producing clones.
For retroviral vector transfection 5x105 PT67 cells were plated in 25cm2 flasks 24h before
transfection. Two-hours previous transfection the complete high glucose DMEM medium was
replaced by 25µMchloroquine-containing high glucoseDMEM,whichmay increases transfection
efficiency 2-3 fold.
The recommended transfection agent for the RetroPack PT67 cell line is the CLONfectin
reagent by Clontech. The fresh liposome-DNA containing solution was prepared following
the manufacturer instructions. The CLONfectin reagent was re-suspended in HEPES-NaCl
buffer dropwise at concentration of 1µg/µl, vortex gently and placed on ice. Then the solution
A (10µg of pDNA and 300µl serum-free high glucose DMEM) was mixed with the solution
B (10µg of CLONfectin and 300µl serum-free high glucose DMEM) gently and this
transfection solution was incubated at room temperature 30min. Subsequently, 2.4ml of
serum-free high glucose DMEM was added and mixed. After removing the chloroquine-
containing medium the CLONfectin/DNA/DMEM solution was gently applied to the cells.
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The flasks were incubated at 37°C for 3h. Later, the CLONfectin/DNA-containing medium
was removed and the cells were washed once with pre-warmed PBS. Finally, 3ml of com-
plete high glucose DMEM was added to proceed the incubation 24h.
The positive transfectants selection was started 48h post-transfection by the replacement of
the complete DMEM by G-418 (600µg/ml)-containing DMEM in the cell cultures.
2.3.7.3 Virus collection and storage
(Figure 15)
All security rules were followed to avoid any biological contamination in the working
area.
Twenty-six hours post-transfection was started the virus-containing-medium collection. The
virus-containing-medium was aspirated from the culture flask and filtered through 0.45-µm
cellulose acetate filter (low protein binding to preserve the virus). The filtrate was alicuoted in
cryo-tubes and frozen in dry ice. Then the cryo-tubes were stored at 70°C until be used.
2.3.7.4 Infection of HeLa cells
(Figure 15)
All security rules were followed to avoid any biological contamination in the working
area.
For HeLa infection 2x105 cells were plated in 25cm2 flasks. The next day a pool of Fra-1
carrying viruses was prepared and two dilutions, 1:2 and 1:10, of the virus-containing-medium
were tested to infect the HeLa cells. The infection mix contained the virus-containing-medium
at the corresponding dilution in complete DMEM and 4mg/ml of Polybrene (Sigma), which
reduces charge repulsion between the virus and the cellular membrane. As control HeLa cells
were infected with a pool of viruses carrying the empty vector pLXIN. Twenty-four hours post-
infection the DMEM was replace by DMEM-G-418 (1mg/ml) in order to start the Fra-1
expressing-cells selection, two days later the non-infected cells started to die. The selection
proceeded for seven days more, then the resistant clones were pooled and nuclear-cytoplasm
extracts and RNA were prepared.
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III. RESULTS
3.1 RARβ trans-repression of AP-1 transcription factor
3.1.1 RARβ expression in HeLa RARβ transfected cells
In HeLa cells has been shown low expression of RARα and RARγ and almost undetectable
levels of RARβ (Si et al., 1996). In order to determine the effect of RARβ constitutive expression
in HeLa cells, they were stably transfected with a pbact RARβ expression vector (Geisen et al.,
2000). This plasmid contains the cDNA of the human RARβ2 gene under the control of the
human β actin promoter. The transfected cells were selected for G-418 resistance, cloned and
expanded. Dr. Elisabeth Schwarz (DKFZ, Heidelberg) kindly provided the clones for further
research.
The expression of the RARβ exo-gene in HeLa clones was analyzed at RNA and protein levels.
As a control, HeLa cells under un-stimulated conditions and after 3 days of treatment with all-
trans-retinoic acid (atRA) at pharmacological dose of 10µM were used.
Figure 16 shows that inHeLa cells, cultured inmedia supplementedwith charcoal stripped serum (in
order to reduce the levels of retinoids contained in the serum), theRARβ expressionwas undetectable
both at RNAand protein level. However, RARβ expression in HeLa cells was increased after 3 days
of retinoic acid treatment.As expected, the clones expressed higher levels ofRARβRNAand protein
in the absence of exogenous ligand addition. Consistent with a previous report (Geisen et al., 1997),
the induction of RARβ expression, endogenously by atRA or exogenously by the transgene had no
effect on the biosynthesis of RARα.
Figure 16 Induction of the endogenous RARβ expression by atRA and stable ectopic expression of RARβ in
HeLacells.A. SemiquantitativeRT-PCRproducts byRARβ, RARα andGAPDH-specific primer sets.Control represents
untreated cells; 3d atRA, cells treated with all-trans-retinoic acid for about 72h; clone β1 and β2, the stable transfected
clones that express the receptor in the absence of exogenous added ligand. B. Immunoblot analysis of nuclear
extracts (25µg per lane) separated in two identical SDS-10% polyacrylamide gels followed by electrotransfer and
incubation with specific antibodies. Equal loading and protein transfer was confirmed by incubating the filters with
an anti actin antibody.
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The functionality of endogenous and exogenous RARβ proteinwas tested by transient transfection
of luciferase gene under the control of the promoter region of the RARβ gene. Figure 17 shows
the induction of luciferase expression after 4h of retinoic acid treatment. The induction shows
that the stably transfected gene generate a functional protein.Additionally, as shown in panel B,
it is interesting that the endogenous activity of the RARE promoter is much higher in the clones
when are compared to HeLa cells. This implies a different basal activity between RARβ clones
and HeLa with respect to the expression of genes driven by RARE containing promoters in the
absence of ligand.
Figure 17 RARE-Luciferase activity in HeLa and the stable transfected clones. RARE-Luciferase reporter
construct, was cotransfectedwith SV-40-β-galactosidase. One-day post transfection, cells were splitted in two identical
plates.After 40h, one of the plates was treated with 10µMatRAfor 4h.A. The cells were assay for luciferase activity
and each value was normalized according to the β-galactosidase activity and compared with the untreated control to
define the fold induction. The untreated controls were normalized and arbitrarily set as 1. Data represent the results
from three independent experiments. B.A representative experiment showing the row data for the luciferase activity in
order to compare the basal (*) and induced (**) promoter activation in HeLa and HeLa RARβ clones.
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3.1.2 Ectopic RARβ expression leads to a selective reduction of AP-1
RARβ is known to be a negative regulator ofAP-1 transcription factor activity (Van deKlundert
et al., 1995; Huang et al., 1997) but this has not been tested so far in cervical cancer cells. Figure
18 shows a reduction between 70-80% of the AP-1 content in the clones in comparison with
HeLa parental cells in the absence of exogenous added ligand. HeLa cells treated for 3 days with
retinoic acid show a reduction in theAP-1 content of about 60%. Note that the reduction of AP-
1 was selective since the binding of the transcription factor Oct-1 to its cognate recognition
sequence shows no variation between the clones and the parental HeLa cells.
Figure 18 The AP-1 content in the HeLa RARβ clones is reduced in the absence of retinoic acid treatment.
EMSAusing 32P-labeled oligonucleotides specific forAP-1 or Oct-1 sequences. Nuclear extracts of HeLa untreated
cells (control), HeLa treated 3d with atRA or HeLa RARβ clones were analyzed. Quantitation of the AP-1 content
was performed by PhosphorImager.
3.1.2.1 Effect of RARβ expression on individual AP-1 family members
To analyze whyAP-1 was down-regulated, the mRNA and protein levels ofAP-1 family
members was determined (Figure 19). AP-1 content of c-Jun, Fra-1 and c-Fos in HeLa and
HeLa RARβ clones was quantified by PhosphorImager analysis. RARβ cells have 85-92%
less c-Jun in the AP-1 than the HeLa parental cells, the Fra-1 content was approximately 2
times more for RARβ clones in comparison with HeLa and c-Fos was almost unaltered
between HeLa and HeLa RARβ clones. The cellular content of JunB, JunD and ATF-2 was
comparable between HeLa and HeLa RARβ clones, and no significant differences were
observed.
Since c-Jun has been reported as the main dimerization partner in HeLa cells (Soto et al.,
1999; Soto et al., 2000) and Jun family members are necessary for the binding of AP-1 to
DNA, one can conclude that the down regulation of AP-1 in the RARβ clones is mainly due
to the strong reduction of c-Jun protein. As c-jun mRNA is present in the RARβ clones at
detectable levels, the c-Jun protein reduction must be a post-transcriptional phenomenon.
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Figure 19 Reduced AP-1 content in RARβ clones due to post-transcriptional down regulation of c-Jun. A.
Semi-quantiative RT-PCR. B. Western blot analysis for different members of the AP-1 family, the sizes of PCR
products and molecular weight of the proteins are indicated.
3.1.2.2 Mechanism of c-Jun down regulation
Figure 20 Schematic representation of c-Jun phosphorylation sites at the N and C-terminal domains
As we observe c-Jun down regulation in the RARβ clones, the role of Jun N-terminal kinase (JNK)
in the c-Jun degradationwas analyzed (Musti et al., 1997). Two possibilities can be envisioned: first
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the JNK is unable to be activated (phosphorylated) and this is the reason why c-Jun is degraded.
Second, the JNK is activated but the presence of RARβ leads to an increase in the content of
MAPK phosphatase 1 (MKP-1), which de-phosphorylates the activated JNK and blocks its
function resulting in the c-Jun instability. Additionally, it has been suggested that retinoic acid
can mediate activation of glycogen synthase kinase 3 (GSK-3), I therefore tested whether c-Jun
phosphorylation by GSK-3 (RARβ activated) can result in diminished DNA binding and c-Jun
degradation (Figures 20 and 21).
Figure 21 Schematic interplay between retinoic acid and kinases c-Jun related
To induce JNK activation tumor necrosis factor α (TNFα) treatment was used. Differential JNK
activation (phosphorylation), MKP-1 expression (at protein level) and GSK-3 inactivation
(phosphorylation) between HeLa and HeLa RARβ clones was evaluated. Figure 22 shows that JNK
is activated in the clones to higher levels than in HeLa parental cells, MKP-1 expression is compara-
ble and the active form of GSK-3, isotypes α and β, is present in all cell lines at similar levels.
Figure 22Westernblot analysis forkinases andphosphatases related in the c-Jun stabilization.Thirtymicrograms
of total extract per lane were separated in SDS-10% polyacrylamide gels. Equal loading and protein transfer were
confirmedby incubating the filterswith anti-actin antibody.The filters reprobed for the different antibodieswere stripped
in 0.2N NaOH.
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These results indicated that JNK activation is not responsible for the c-Jun down regulation
which is in contrast to other systems reported in the literature (Lee et al., 1998; Moreno-Manza-
no et al., 1999; Gonzalez et al., 2000; Li et al., 2001). Additionally, the GSK-3 activation is not
playing a role in the RARβ effect on c-Jun stability.
To check if the activation of JNK and the phosphorylation of c-Jun was coupled or whether
RARβ interfere between JNK activation and c-Jun phosphorylation, an activity test using
exogenous c-Jun was performed. In the figure 23 the activity test reveals that phospho-JNK is
active and able to phosphorylate exogenous added c-Jun protein. Consequently, the absence of
the c-Jun protein in the HeLa RARβ clones is not due to the inactivation, inhibition or
dysregulation of the JNK.
Figure 23 JNK activity of HeLa parental cells and HeLa RARβ clones after 15TNFα treatment. JNK from
cell extracts was pulled down using c-Jun fusion protein beads follow by the kinase reaction in the presence ofATP.
The JNK activity was analyzed byWestern blot using a specific phospho-c-Jun antibody. Note a slight reduction in
the molecular weight of the c-Jun fusion protein in comparison with the cellular c-Jun (see materials and methods
section 2.2.3.5). Equivalent loading and protein transfer were confirmed by incubating the filters with an anti total
JNK antibody.
3.1.3 Increase of c-Jun protein leads to AP-1/DNA-binding reconstitution in HeLa
RARβ clones
As was showed in the previous sections, AP-1 reduction was mainly due to c-Jun down
regulation. Next I checked whether an increase in the c-Jun content in the cells could result in
AP-1 binding reconstitution in the HeLa RARβ clones. The different strategies used in order to
reach this aim will be analyzed in the next sections.
3.1.3.1 Overexpression of exogenous c-Jun in HeLa and HeLa RARβ clones
The first strategy used to increaseAP-1 was c-Jun overexpression by transient transfection
in HeLa and HeLa RARβ clones. The electrophoretic mobility shift assay EMSA showed a 2-
fold increase in AP-1 binding in the RARβ clones as well as in HeLa parental cells. However,
the c-Jun and P-c-Jun in the clones remain undetectable in Western blot in contrast to the HeLa
parental cells, in which c-Jun content is highly increased and phospho-c-Jun is detectable after
protein overexpression without JNK activation (Figure 24).
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Figure 24 c-Jun overexpression in HeLa and HeLa RARβ clones.A. Nuclear extracts of HeLa and HeLa RARβ
clones control and transiently transfeted with RSV-c-Jun were prepared for EMSAwith AP-1 oligonucleotide. B.
Western blot for c-Jun and phospho-c-Jun was performed using the same extracts, in which the amount of protein
was normalized to the β-galactosidase leading to different intensity of the actin signal. Amount of protein and
transfer was monitored incubating the filters with anti-actin antibody, the molecular masses of the proteins are
indicated.
The results suggest that the transfected protein is unstable in the HeLa RARβ clones, since
in contrast to HeLa parental cells, it can not be accumulated, even under overexpressed
conditions as is shown in the Western blot. However, although c-Jun was not visible under
Western blot conditions, using EMSA a highly sensitive method, it is possible to detect an
increase in the AP-1 complex. At this point, it was postulated that c-Jun is regulated via
differential half-life in HeLa and HeLa RARβ clones. In the following experiments the aim
was stabilize the c-Jun protein and accumulate it by different mechanisms in order to restore
AP-1 levels in the HeLa RARβ clones.
3.1.3.2 Tumor necrosis factor α treatment in HeLa and HeLa RARβ clones
As was shown in figures 22 and 23, TNFα treatment induces phosphorylation and
activation of JNK. However, it was not tested whether this has an effect on c-Jun protein
accumulation.
EMSA super shift for c-Jun revealed a clear increase in the AP-1 content in the cells after
TNFα treatment. More than half of the AP-1 signal is shifted after the addition of the c-Jun
antibodies (Figure 25 panel A).
In contrast, Western blot results of RARβ clones (panel B) did not show any increase in the
content of c-Jun after TNFα treatment. Nevertheless, phosphorylated c-Jun was augmented in
comparison with the control untreated cells. This rise in phospho-c-Jun can explain the increase
of binding between AP-1 complex and its recognition sequence (Figure 25 panel A).
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Figure 25TNFα treatment in HeLa andHeLaRARβ clones.A.AP-1 EMSAusing nuclear extracts fromHeLa and
HeLa RARβ clones control and 30 min treated with TNFα. For super-shift 1µg of antibody anti-phospho-c-Jun was
added.B.Western blot for c-Jun and phospho-c-Jun was performed using the same extracts. Equal loading and transfer
was monitoring incubating the filters with an anti-actin antibody. The molecular weight of the proteins are indicated.
It has been shown that treatment of the cells with all-trans-retinoic acid (atRA) impairs JNK
activation by inhibiting its phosphorylation. Section 3.1.2.2 showed that RARβ is not inhibiting
the JNK phosphorylation or activity but it was still unclear whether the exogenous addition of
the RARs ligand could inhibit JNK in HeLa cervical cancer cells. To test this possibility, HeLa
RARβ clones were treated for 3 days with atRA 10µM and then with TNFα (500U/ml) 30
minutes. The results of the figure 26 shows that the phosphorylated form of JNK is comparable
with and without atRA treatment, indicating that retinoic acid treatment has no effect on JNK
activation by TNFα in HeLa RARβ clones. This finding is in contrast to observations made in
other cancer models (Lee et al., 1998; Moreno-Manzano et al., 1999; Li et al., 2001).
Figure 26 JNK activation inHeLaRARβ clones control andTNFα induced after 3 days treatment with retinoic acid.
TotalSDSextractswereprepared fromcells treatedwithDMSOoratRAafter JNKactivationbyTNFα. Fortymicrograms of
total extract per lane were separated in two identical SDS-10% polyacrilamide gels.An anti-actin antibody was used
as a control for protein loading and transfer.
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JNK activation by TNFα was not able to stabilize the c-Jun protein to the levels detected in
HeLa parental cells, and c-Jun remained undetectable after TNFα treatment by Western blot.
The increase of AP-1 can be explained by the phosphorylation of the c-Jun present in the cells
(Figure 25), which lead to a higher affinity ofAP-1 binding, nevertheless an undetectable increase
of c-Jun protein can not be ruled out.
3.1.3.3 Proteasome inhibitor treatment of HeLa and HeLa RARβ clones activates
the JNK pathway
Since proteasome inhibitors can induce the activation of the Jun-N-terminal kinase (JNK)
(Meriin et al., 1998; Nakayama et al., 2001a), HeLa and HeLa RARβ clones were treated with
proteasome inhibitor MG-132 for 8h. As depicted in the figure 27 panel A a high c-Jun
accumulation in the RARβ cloneswas observed.Moreover, c-Jun andATF-2were phosphorylated
(panel A) and as consequence of the auto regulatory loop the level of c-jun mRNA expression
was increased (panel B). This can be considered as an indirect evidence of JNK activation by
MG-132 and suggests that the increase of c-Jun was not only due to an accumulation of the
protein by proteasome blocking but additionally involved de novo synthesis. To determinewhether
JNK was activated by MG-132 treatment, an activity assay was performed. The panel C shows
that MG-132 treatment activates JNK and confirms that in HeLa cervical cancer cells RAR
receptors do not inhibit JNK activation.
Is important to note that c-Jun induction and accumulation has no effect in the RARβ transgene
expression at mRNA or protein levels (Figure 27 panels A and B).
Figure 27 JNKactivation, c-Jun induction and accumulation afterMG-132 treatment.A.Western blot: Twenty-
five micrograms nuclear extracts from cells treated 8h with 20µM MG-132 (+) and untreated controls (-). After
electrotransfer, the blots were incubatedwith the c-Jun, phospho-c-Jun,ATF-2, phospho-ATF-2 andRARβ antibodies.
Equal loading was confirmed with an anti-actin specific antibody. B. mRNA expression of c-Jun and RARβ genes
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after 8hMG-132 treatment detected by semi-quantitative RT-PCR. The products were separated in 1% agarose gels.
C. JNK activity after 8h MG-132 treatment. JNK from cell extracts was pulled down using c-Jun fusion protein
beads follow by the kinase reaction in the presence of the ATP. The JNK activity was determined by Western blot
using a specific phospho-c-Jun antibody. The cells untreated showed not kinase activity and were unable to
phosphorylate exogenous added c-Jun (see figure 23).
The effect of the c-Jun accumulation on AP-1 binding was analyzed by EMSA. As expected
according to PhosphorImager analysis the AP-1 content increased in RARβ clones after MG-
132 treatment to 70-150% (being HeLa parental cells 100%, figure 28 panel A). To exclude a
non-specific general up regulation of other transcription factors, Oct-1 binding is shown.Addition
of anti-phospho-c-Jun antibodies shifted about 50% of the AP-1 signal (Figure 28 panel B).
Figure 28 AP-1 reconstitution after c-Jun accumulation by MG-132 treatment. A. EMSA using 32P-labeled
oligonucleotides specific for AP-1 or Oct-1, 2µg of nuclear extracts from cells control or treated 8h with MG-132
were used for the binding reaction. Cells treated 8h with 20mM MG-132 (+) and untreated controls (-). B. Super
shift analysis of the c-Jun content.After 30min incubation at room temperature of nuclear extractswith oligonucleotides
specific for AP-1 1mg of c-Jun monoclonal antibody was added following by an extra incubation of 60min at 4°C.
In order to test whether the accumulated c-Jun protein was functionally reconstituted in the
AP-1 complex, cells were transfected with a plasmid containing the luciferase gene under
the control of TPA responsive element (TRE-Luc). The results are presented in the figure
29. There was 5-7 fold induction when stimulated cells are compared with control cells,
showing that AP-1 restored after c-Jun induction and accumulation by MG-132 was
functionally active.
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Figure 29AP-1 activity using TRE-Luciferase reporter assay in the RARβ clones treated withMG-132. Cells
were co-transfected with plasmids TRE-Luc and SV-40-β-galactosidase. One day after transfection HeLa RARβ
clones were splited in two identical plates. Thirty eight hours post transfection one of the plates was treated with
20µMMG-132 for 8 h. Cell extracts were assayed for luciferase activity, each value was normalized according to
the β-galactosidase activity and compared with the untreated control to define the fold induction in each case. The
untreated controls were normalized and arbitrarily set as 1. Data represent the results from three independent
experiments.
The MG-132 experiments showed that is possible to re-induce c-Jun protein expression in the
HeLa RARβ clones, by blocking proteasome degradation, and suggested that the activation of
the JNK is involved. Next it was analyzed whether a sustained induction of JNK is enough to
revert the RARβ effect.
3.1.3.4 Serum starvation and stimulation results in c-Jun induction and AP-1
binding reconstitution in HeLa RARβ clones
Own results from the laboratory have shown that the TNFα stimulus is strong but transient:
the duration of JNK activation is less than 60minutes. I therefore tested amore sustained stimulus
to find out if this could cause c-Jun accumulation (stabilization).
To achieve this aim the cells were starved for 24h and stimulated by 10% fetal calf serum (FCS)
addition for 2h. In figure 30 panel A is an EMSA in which AP-1 binding is reconstituted after
serum induction with an increment in the signal of 3-4 fold.
In order to determine if this increment in AP-1 correlates with c-Jun accumulation a Western
blot for c-Jun was performed. In figure 30 panel B a clear protein accumulation can be visualized
after serum induction. This correlates with an increase in the synthesis of mRNA (Figure 30
panel C).
fra-1 mRNA synthesis is transcriptionally activated by AP-1 through a consensus AP-1 site
found in the first intron of the fra-1 gene (Bergers et al., 1995; Griffiths et al., 1998). To monitor
Fra-1 expression aWestern blot was performed. The figure 30 panel B shows that Fra-1 protein
after serum stimulation was induced, which also suggests functionality of the reconstituted AP-1
complex.
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Figure 30 c-Jun induction andAP-1 reconstitution by serum stimulation.A. EMSAforAP-1. Cells were depleted
from serum and then stimulated for 2h with 10% FCS. Nuclear extracts were prepared and 2µg of protein wasmixed
with the probe. Controls are untreated cells; (-) FCS 24h, cells depleted from serum during 24 hours and (+) FCS 2h,
cells depleted from serum 24h and then stimulated with 10%FCS for 2 hours.B.Western blot analysis from the same
extracts. Twenty-five micrograms of the nuclear protein was loaded per lane. The filters were probe with c-Jun, Fra-
1 and anti-actin antibodies.C. Semi-quantitative RT-PCR for c-jun using RNAfrom the same preparations. GAPDH
was used as internal control.
In contrast to the transient JNK stimulation of TNFα treatment, the longer FCS stimulus sufficed
to induce and accumulate c-Jun protein to detectable levels in the HeLa RARβ clones.
In order to test if this reconstitution of AP-1 can be abrogated by an activated RARβ receptor,
HeLa and HeLa RARβ clones were treated 3 days with all-trans-retinoic acid (atRA), starved 24
hours and stimulated by serum 10% during 2 hours. The results are presented in the figure 31.
The atRA treatment followed by serum induction led toAP-1 binding reconstitution but the pre-
treatment with atRA diminished the effect of the serum stimulation nearly 2.5 to 3.0 times.
Nevertheless, the AP-1 content after serum stimulation under atRA treatment is higher in
comparison with un-stimulated cells. In consequence was observed a reconstitution of theAP-1
binding in the presence of atRA which argue against a blocking of the JNK pathway due to
retinoid treatment.
However, there was a slight reduction in the c-Jun protein content after serum stimulation in
atRA pre-treated cells, which could be the reason for the reduction in the AP-1 content under
such conditions. It is important to remember that retinoic acid treatment stimulate all retinoic
acid receptors and the reduction in the AP-1 binding reconstitution may not exclusively be due
to RARβ driven mechanism.
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It is surprising that although c-Jun content in the clones is slightly reduced, the phosphorylated
form of c-Jun is comparable between serum stimulated cells in the presence or absence of retinoic
acid treatment. Evidently Jun-N-terminal kinase (JNK) is not the target for the RARβ receptor.
Additionally, is suggested that phospho-c-Jun is not degraded in the clones and this correlates
with reports that JNK phosphorylation of c-Jun leads to stabilization of the protein (Musti et al.,
1997).When the protein is not phosphorylated it becomes a substrate for proteasome degradation,
in a process which is RARβ driven (Figure 19).
Figure 31 Serum induction after retinoic acid treatment. Cells were treated with pharmacological dose of all-
trans-retinoic acid (10µM) during 3 days and simultaneously starved from serum 24 hours and induced by 10%FCS
for 2 hours. After the treatment cells were harvested and nuclear extracts were prepared. A. EMSA for AP-1 oligo
was carried out with 2µg of the nuclear extracts. B. Western blot for c-Jun and phospho-c-Jun was performed using
the same extracts. Equal loading and transfer was monitored with an anti-actin antibody. The molecular masses are
indicated.
The fetal calf serum stimulation leads to mitogen-activated protein kinase (MAPK) activation,
including JNK phophorylation and activation through the protein kinase C pathway (Furuse
et al., 1997). Based on the previous results it is possible to suggest that c-Jun accumulation
depends on its stabilization, which is mainly due to c-Jun phosphorylation by JNK. The
stimulus leading to JNK activation must be strong and sustained to allow the stabilization
of c-Jun molecules by phosphorylation. This phosphorylated c-Jun will enhance the c-jun
gene expression by a feedback process and will result in further c-Jun accumulation.
3.1.3.5 Constitutively active proteins that belong to the JNK pathway cause c-
Jun induction and AP-1 binding reconstitution in HeLa RARβ clones
Twoproteins can activate Jun-N-terminal kinase (JNK)pathway:Ha-rasmt protein (12Gly->Val)
and a constitutive active mutant of the MEKK1 (mitogen-activated protein kinase kinase 1).
MEKK1∆ lacks theN-terminal regulatory domain (Minden et al., 1994; Lin et al., 1995).MEKK1
is described as the most potent activator of JNK (Xia et al., 2000) (Figure 32).
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Figure 32 JNK pathway for different MEKK1 activating stimuli.
HeLa andHeLa RARβ clones were transiently transfected with Ha-rasmt orMEKK1∆ expression
vectors and after 48h nuclear or total extracts were prepared.
Figure 33 shows AP-1 binding reconstitution after Ha-rasmt or MEKK1∆ transfection. As was
anticipated, AP-1 binding was increased after transfection: Three fold for Ha-rasmt protein and
nearly 5 fold for MEKK1∆. The Oct-1 binding activity, used as a specificity control, was not
modulated in its binding.
Figure 33 AP-1 EMSA from cells transient transfected with mutant Ha-ras or MEKK1∆. Nuclear extracts
were prepared 48h post-transfection. Two micrograms of the protein was incubated with the 32P-labeled AP-1 or
Oct-1 oligo. After 30min of room temperature incubation the 5,5% polyacrylamide gels were loaded.
To test the effect of transient transfection with Ha-rasmt andMEKK1∆ on c-Jun stabilization and
messenger RNA induction Western blots and semi-quantitative RT-PCRs were performed. The
results showed an increase in the c-Jun at RNA level for Ha-rasmt and MEKK1∆ transfected
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cells. However, c-Jun phosphorylation in the RARβ clones was only detected after MEKK1∆
transfection. Additionally, Fra-1 as an endogenous reporter gene for AP-1 activity, showed
induction at RNAand protein level in cells transiently transfectedwith bothHa-rasmt andMEKK1∆
(Figure 34 panels A and B). The unchanged expression of c-fos in the transfected cells showed
that the increase of c-jun and fra-1was specific and did not represent a general effect on all AP-
1 familymembers (Figure 34 panelA). Note that the RARβ expression appeared to be unaffected
and the AP-1 binding reconstitution and c-Jun accumulation did neither changed the RARβ
RNA expression nor protein content (Figure 34 panels A and B).
Figure 34 Expression of someAP-1 familymembers afterHa-rasmt orMEKK1∆ transfection.A. Expression of
AP-1 family members and RARβ receptor. Total RNA was reverse-transcribed and PCR reaction was performed
with specific primers for c-jun, fra-1, c-fos,RARβ andGAPDH as internal control.B.Western blot analysis of 25µg
of nuclear protein from cells transfected with Ha-rasmt and MEKK1∆. Forty-eight hours post-transfection nuclear
extracts were prepared.After electrotransfer, the filters were incubated with the c-Jun, Fra-1 and RARβ antibodies.
Anti-actin antibody shows equal loading and transfer.
Since c-Jun accumulation was undetectable in the HeLa RARβ clones after transient transfection
with Ha-rasmt, and because Fra-1 was increased, an EMSA supershift was performed (Figure
35).As expected c-Fos content was unchanged in the HeLa or HeLa RARβ clones under control
or transient transfected conditions, instead is possible to suggest that the c-Fos content was even
reduced due to the increase in theAP-1 complex after transfection. In the case of c-Jun and Fra-
1 it is possible to observe a clear increase in the incorporation of these proteins in the AP-1
complex after transfection with Ha-rasmt or MEKK1∆. The PhosphorImager quantitation shows
an increase of Fra-1 in the AP-1 complex of 3 times for HeLa parental cells and 1.5 times for
each clone (the AP-1 complex of the clones has nearly 2 times more Fra-1 than HeLa under
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control conditions see section 3.1.2.1). In the case of c-Jun the increment was nearly 3 times
for Ha-rasmt (however the protein was undetectable inWestern blot) and 5 times for MEKK1∆.
Basically is possible to say that c-Jun/c-Jun homodimers and c-Jun/Fra-1 heterodimers formed
the AP-1 complex after Ha-rasmt and MEKK1∆ transfection.
Figura 35 AP-1 incorporation of c-Fos, Fra-1 and c-Jun after transient transfection with Ha-rasmt and
MEKK1∆. Two micrograms of nuclear extracts were mixed with 32P-labeled AP-1 recognition sequence.
After 30min of room temperature, 1µg of the corresponding antibody was added and the incubation was
prolonged for 1h. The binding reaction was loaded on a 5.5% polyacrylamide native gel.
I had shown that activators of Jun-N-terminal kinase (JNK) pathway allow the reconstitution
of AP-1 binding, but the c-Jun protein level depends on the strength and duration of the
induction. In order to check if MEKK1∆ is a better inductor of JNK in the HeLa RARβ
clones, leading to a more activeAP-1 complex due to c-Jun stabilization by phosphorylation,
c-jun gene induction and protein accumulation, a reporter gene assay was performed.
Luciferase under the control of TPA response element was co-transfected with the SV-40-β-
galactosidase plasmid and the Ha-rasmt or MEKK1∆ vectors. Figure 36 shows a comparison
between the normalized TRE-Luc fold induction in cells transfected with Ha-rasmt, MEKK1∆
and control TRE-Luc activity. The results show that MEKK1∆ is a stronger activator of AP-
1 activity than Ha-rasmt (nearly 3 times more TRE-Luc activity for MEKK1∆ transfected
cells in comparison with Ha-rasmt transfected cells as is shown in the figure 36).
Results 78
Figure 36 TRE-Luc induction in cells transfected with Ha-rasmt or MEKK1∆. Semi-confluent cells were triple
transfected with TRE-Luc, SV-40-β-galactosidase and Ha-rasmt or MEKK1∆. Forty-eight hours after transfection, the
cells were harvested and extracts were assay for luciferase activity. Each value was normalized according to the β-
galactosidase activity and comparedwith the controls.The controlswere normalized and arbitrarily set to 1. Experiments
were performed by duplicate.
Finally, an activity test (Figure37) showed the strongest activationof JNKafterMEKK1∆ transfection
in HeLa and HeLa RARβ clones, reflected in the c-Jun fusion protein phosphorylation.
Figure 37 JNKactivity 48h after transient transfectionwithMEKK1∆. JNK from the cell extractswas pulled down
using c-Jun fusion protein beads followed by the kinase reaction in the presence of the ATP. The JNK activity was
determined byWestern blot using a phospho-c-Jun antibody specific for the c-Jun fusion protein. Equivalent loading and
protein transferwere confirmedby incubating the filterswith an anti total JNKantibody, (-) refers to untransfected controls.
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3.1.4 Role of RARβ on protein degradation
The alteration in the rate of proteasomal degradation by RARs is a mechanism described in
the control of some proteins of the cell cycle. The treatment of cancer cells with all-trans-retinoic
acid inhibits the expression and activity of cyclin D1, cyclin E, CDK2 and CDK4, increased p27
levels and shifted Rb to a hypophosphorylated state (Langenfeld et al., 1997, Sueoka et al.,
1999; Dow et al., 2001). It has been postulated that regulation of many of these proteins is a
post-translational mechanism that involves the ubiquitin-proteasome pathway . In order to check
if the down regulation of c-Jun could be coupled to the post-translational regulation of some of
these cell cycle proteins in the HeLa RARβ clones, Western blots were performed. The results
shown in figure 38 show a slightly lower cyclin D1, when HeLa and the RARβ clones were
compared.
All the other proteins analyzed remain at comparable levels, except p53 levels that showed a
slight up regulation and the cyclin dependent kinase (CDK) inhibitors p21 and p27, which were
strongly up regulated in the RARβ clones when compared to the HeLa parental cells.
Figure 38 Effect of the constitutive expression of retinoic acid receptor β on cell cycle regulatory proteins.
Protein extracts were prepared from HeLa and HeLa RARβ clones under control culture conditions. Twenty-
five micrograms of protein were loaded per lane in a 10% SDS-polyacrylamide gel. After electrotransfer the
filters were incubated with specific antibodies against cyclin E (CycE), cyclin dependent kinase 2 (CDK-2),
S-phase kinase associated protein 2 (Skp-2), Retinoblastoma (Rb), p21, p27, Cyclin D1 (CycD1) and p53.
Equal loading and transfer was monitored by incubation of the membranes with an anti-actin antibody. The
molecular weight of the proteins is indicated. Total extracts CycD1, CDK-2, Skp-2, Rb and p27. Nuclear
extracts CycE, p21 and p53.
The induction of the cyclin-CDK inhibitors as well as the reduction in the cyclin D1 is
probably responsible for the slower growth rate of the RARβ clones in comparison with the
HeLa parental cells (Figure 39). As expected, the clones have a slower growth than the
parental cells without evidence of cell death.
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Figure 39 Cell growth curve for HeLa and HeLa RARβ clones. Cells were plated at 1,5x106 in 60cm2 dishes.
Cells were trypsinized and counted. HeLa cells that growth much more faster where counted by duplicate and the
average was calculated.
These results are in favor of a degradation pathway specifically directed against c-Jun, because
the post-translational down regulation of cell cycle regulators exhibits different tendencies in
comparison with c-Jun in the RARβ clones. However it was shown that retinoic acid receptors
can modulate the proteasome machinery leading to the stabilization of some proteins and the
degradation of the others. The results presented in the section 3.1.3 strong suggest that proteasomal
targeting plays a role in the c-Jun degradation and that degradation is stimulated by RARβ.
3.1.4.1 Role of POH1 in c-Jun stabilization in HeLa RARβ clones
Recently, has been reported that a regulatory subunit of the proteasome, POH1 (Human
Pad1 homolog), can stabilize c-Jun and is important for AP-1 activation (Spataro et al., 1997;
Nabhan et al., 2001). A link between RARs signalization and POH1 activity has not been
described, but inhibition of this kind of proteasomal subunits can lead to increasing rate of c-Jun
protein degradation in HeLa RARβ clones.
Human Pad1 is an enzyme found in the lid of the regulatory part of the proteasome complex. It
is a de-ubiquitinating enzyme that efficiently removes the ubiquitin. The proteins to be degraded
must enter the proteasomes cylinder through a narrow opening end. It is likely that the poly-
ubiquitin chain must be removed to allow the whole protein to be fed through the opening and
hydrolysed (Wilkinson, 2002).
How this protein contributes to c-Jun stabilization is presently not understood. But it seems
likely that the stabilization of c-Jun is caused by an intrinsic activity of the POH1, which does
not require integration of the protein into the proteasome lid. Under POH1 overexpressing
conditions the half life of the c-Jun protein has been shown to increase by more than 1 hour. It is
Results 81
possible that POH1 functions as a c-Jun de-ubiquitinase but is not clear how this activity is
selective towards c-Jun. By targeting c-Jun andmodulating its stability, POH1 represents a major
mechanism for regulation the transcriptional activity of AP-1 (Spataro et al., 1997; Nabhan et
al., 2001).
In order to test if POH1 has some relevance in the degradation phenomenon that leads to c-Jun
down regulation in HeLa RARβ clones, the steady-state content of poh1 was analyzed at the
RNA level under control and MEKK1∆ or Ha-rasmt transient transfection conditions.
As depicted in figure 40 panel A no differences are observed in the poh1 mRNA expression
between HeLa and HeLa RARβ clones under control or stimulated conditions. Figure 40 panel
B shows aWestern blot for the POH1protein. The results show that the protein is in the cytoplasmic
fraction where 70% of the proteasome machinery is located. Additionally it is clear that the
proteasome inhibitor MG-132 did not increase the protein level in the cells.
Figure 40 POH1 expression at RNA and protein level in HeLa and HeLa RARβ clones. A. Semiquantitative
RT-PCR for poh1mRNAexpression. One microgram of RNAwas used in the RT reaction. For PCR, 1µl of the RT
reaction was amplified with the specific pair of primers. GAPDHwas used as internal control. (+) refers to Ha-rasmt
or MEKK1∆ transfected cells. B. Western blot to detect POH1 protein expression. POH1 polyclonal antibody was
kindly provided by Dr. Norbury, Oxford University. Anti-actin antibody confirm equal loading and transfer.
The cytoplasmic content of the POH1 protein is comparable between HeLa and HeLa RARβ
clones, which argue against quantitative differences of POH1 to explain the presence or
absence of c-Jun. However, it is possible that RARβ or a gene target interact with the POH1
to inhibit its function. To evaluate this possibility, transient transfection experiments with
the POH1 expression vector were performed. The results in figure 41 panel A show an
increase of c-Jun in theAP-1 complex in the clones and in the parental cells as was determined
by EMSA super shift assay. By PhosphorImager quantitation was detected a 1.3-1.6 fold
increase of c-Jun in the AP-1 complex. This effect was specific for AP-1 transcription factor
because no changes were observed in Oct-1 binding. However, the c-Jun content in Western
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blot was barely detected even after POH1 transient transfection (Figure 41 panel B). To
check if the c-Jun incorporated in the AP-1 complex leads to more active AP-1 transcription
factor, Fra-1 expression was determined by Western blot. The induction of Fra-1 protein
was discrete but reflex a differential AP-1 activity, suggesting that the increment of AP-1 by
POH1 transient transfection results in a slight more active transcription factor.
Figure 41 POH1 transient transfection in HeLa and HeLa RARβ clones. A. EMSA super shift analysis of
cells transfected with 2µg of pCDNA3-HA.POH1 expression vector. Two micrograms of nuclear extract
were incubated with the radioactive label AP-1 or Oct-1 recognition sequence. After 30 minutes at room
temperature, 1µg of anti phospho-c-Jun antibody was added to the AP-1 samples and the incubation was
prolonged for an additional hour. Note that larger exposure time was used for HeLa RARβ clones that is the
reason for the lack of differences in theAP-1 content between HeLa and the clones. B. Twenty-five micrograms
from the same nuclear extracts were used in the Western blot analysis of c-Jun and Fra-1 protein expression.
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3.2 Effect of RARβ expression on HPV-18 oncogenes E6/E7
3.2.1 HPV-18 oncogenes E6/E7 expression in HeLa RARβ clones
The treatment of HPV-18 positive cells with retinoic acid down regulates oncogene expression
(Bartsch et al., 1992) and induces growth arrest (Si et al., 1996), but the mechanism by which
this reduction is achieved has not been analyzed so far. It is as well established that the constitutive
expression of RARβ receptor in HeLa cells leads to retardation of the tumor growth in nude
mice (Geisen et al., 2000 and lab. results). As was showed in the previous section HeLa RARβ
clones grow slowly in culture and cointain higher levels of p53 protein in comparison with HeLa
parental cells (Figures 38 and 39). To test whether this observations are correlated with the E6/
E7 oncogene expression, the RNA and protein content of the oncogenes was determined in the
HeLa RARβ clones.
The results in the figure 42 show a reduction of the oncogene expression on both levels in the
RARβ clones compared to HeLa parental cells. The reduction was detected in the absence of
exogenously added ligand, suggesting that this is basically due to constitutive RARβ expression
in the clones. As control HeLa cells treated with pharmacological doses of all-trans-retinoic
acid (atRA) also exhibit a down regulation of oncogene expression at mRNA and protein levels.
Nevertheless, in this case the reduction can not be assign only to RARβ because the atRA treatment
activated all retinoic acid receptors.
Figure 42HPV-18 oncogene expression inHeLa andHeLaRARβ clones.A. Detection of mRNAlevels of HPV-
18E6/E7 byNorthern blot. RNAquality is shown byRNAgel and equal loading (5µg) is shown by actin hybridization.
B. Western blot for E7 protein. Thirty micrograms of cytoplasmic protein was electrophoresed on a 12%-SDS
polyacrylamide gel. Filter was incubated with an anti-E7 antibody, and subsequently incubated with an anti-actin
antibody used to confirm equal protein loading.
In order to test whether HeLa RARβ clones treated with pharmacological doses of atRA
show further reduction in the oncogene expression, they were cultured 3 days in the presence
of 10µM retinoic acid. Figure 43 shows that retinoic acid leads to further reduction of the
HPV-18 expression in the clone RARβ2, but the oncogene expression is unchanged for the
clone RARβ1.
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Figure 43 E6/E7 oncogene mRNAexpression in HeLa RARβ clones treated with all-trans-retinoic acid.After
treatment of the cells for 3 days with atRA, RNA was extracted and electrophoresed. After transfer, blots were
incubated with HPV-18 probe. RNA quality is shown in the RNA gel and equal loading was monitored by actin
hybridization.
Down regulation in the HPV-18 oncogenes may contribute to the slow proliferation rate of the
RARβ clones.
The transcription factor AP-1, plays an important role in determining the efficiency of HPV
expression (Offord et al., 1990; Butz andHoppe-Seyler, 1993). Constitutive expression of RARβ
receptor in HeLa cells diminishes the AP-1 content on these cells (Figure 18). It was therefore
important to analyze if the AP-1 binding to the upstream regulatory region of HPV-18 was also
reduced in comparison with other cellular proteins controlling HPV transcription.
3.2.2 Analysis of the upstream regulatory region of HPV-18: Protein-DNA interaction
at the enhancer and promoter elements in the HeLa RARβ clones
Figure 44 Schematic overview of HPV-18 Upstream regulatory region.NF-1, Nuclear factor 1;AP-1,Activator
protein 1; Oct-1, Octamer binding transcription factor 1; KRF-1, Epithelial cell-specific transcription factor 1;
GRE, Glucocorticoid response element; Sp-1, SV40 promoter binding protein.
Oligonucleotides carrying the binding sequence for the transcription factors presented in the figure 44
were synthesized and electrophoretic mobility shift assay were performed. Figure 45 panelA shows
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a comparison between the binding of AP-1 to the TRE sequences of collagenase 1 consensus,
HPV-18 enhancer and HPV-18 promoter. The reduction in the AP-1 binding is clear in all three
sequences. PhosphoImager analysis showed that the binding to the enhancer and promoter
sequences is reduced around 70-75% in comparison with HeLa parental cells. The panels B and
C of the figure 45 show that binding of other transcription factors was not reduced, indicating
that RARβ overexpression selectively reduced AP-1.
Figure 45 Protein-DNA interaction for the different regulatory elements of the HPV-18 URR. EMSA
using 32P-labeled oligonucleotides. Nuclear extracts from HeLa untreated cells, HeLa treated 3 days with
atRA or HeLa RARβ clones were analyzed. A. Comparison of AP-1 binding to the TRE sequences of
collagenase 1 (Consensus=C), HPV-18 enhancer (E) and HPV-18 promoter (P). B. Analysis of the transcription
factors, which bind to the enhancer of the HPV-18 URR. C. Analysis of the transcription factors, which bind
to the promoter of the HPV-18 URR.
AP-1 binding reduction correlated with the down regulation of the oncogene expression in
the HeLa RARβ clones. These data are additionally supporting by the reduction of the AP-
1 binding in HeLa cells treated with retinoic acid that as well exhibited less HPV-18 E6/E7
expression.
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3.2.3 AP-1 binding reconstitution and HPV-18 expression
Results described above showed that different treatments could abrogate the RARβ effect
and stabilize/accumulate c-Jun leading to AP-1 binding reconstitution. Additionally, it was
demonstrated that AP-1 increment is functional by a transient reporter TRE-Luciferase assay
or testing the increment of the endogenous marker gene Fra-1.
Postulating that HPV-18 E6/E7 oncogene expression depends on AP-1 and observing a
reduction in HPV transcription in the clones which contain less AP-1, I tested whether AP-
1 binding reconstitution would lead to HPV transcriptional up regulation of the E6/E7
oncogenes.
RNA samples from every treatment which increased AP-1 were analyzed by Northern blot
to check the HPV-18 E6/E7 expression. The different strategies used were exogenous c-Jun
over-expression, tumor necrosis factor α treatment, MG-132 proteasome inhibitor treatment,
serum starvation and stimulation, MEKK1∆ over-expression, Ha-rasmt over-expression and
c-Jun stabilization by transient transfection with POH1.
The RNA samples belong to the same experiments in which an AP-1 binding reconstitution
was observed (Figures 24, 25, 28, 30, 33, 41). The results are shown in the figure 46.
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Figure 46 Northern blot analyses of HPV-18 expression after different treatments for AP-1 reconstitution.
Cells were harvested 48h after transient transfection. The blots were hybridized sequentially with an HPV-18 probe
and actin probe to monitored equal RNA loading and transfer.
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Surprisingly HPV-18 oncogene mRNA expression was not induced and in contrast some of the
treatments even reduced mRNA levels in HeLa parental cells.
To investigate the reason why HPV expression was not increased, I tested whetherAP-1 binding
to the specific AP-1 sequences of the HPV-18 URR was reconstituted. The results depicted in
figure 47 show that afterMEKK1∆ or Ha-rasmt transient transfectionAP-1 binding at the enhancer
and the promoter sequences was restored. Therefore the unresponsiveness of HPV-18 URR can
not be due to an inability ofAP-1 to bind to the specific URR sequences after its induction. Oct-
1 binding activity shows the selective effect over AP-1.
Figure 47 DNAbinding activity of theAP-1 reconstituted at the enhancer and promoter of the URRHPV-18.
Electrophoresis mobility shift assay. Two micrograms of nuclear protein from MEKK1∆ or Ha-rasmt transient
transfected cells were mixed with labeled oligonucleotide.
In order to check if unresponsiveness could be also demonstrated for other promoters that
contain AP-1 binding sites, classical AP-1 regulated genes were analyzed at mRNA level.
The regulation of the metalloproteinase (MMPs) genes has been described to be strongly
dependent on the AP-1 binding sites present in their promoters (Figure 48 panel A) (Benbow
and Brinckerhoff, 1997; Westermarck and Kähäri, 1999; Angel et al., 2001). To analyze
whether the expression of three different metalloproteinases were induced after transient
transfection with MEKK1∆ or Ha-rasmt, RT-PCR was performed. The results presented in
the figure 48 panel B show that the collagenase 1 (MMP-1) and stromyelin (MMP-3) were
not expressed under control conditions in HeLa or HeLa RARβ clones but were induced
after transient transfection with MEKK1∆ or Ha-rasmt. However in the case of the clone
RARβ2 the induction after Ha-rasmt was very weak. In contrast the collagenase 3 (MMP-13)
gene was constitutively expressed and after MEKK1∆ or Ha-rasmt transfection no changes
in its expression were observed.
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Figure 48Metalloproteinases induction afterAP-1 reconstitution.A. Schematic overviewof themetalloproteinases
promoter region. C/EBP-β, CCAAT/enhancer binding protein β; TIE, TGF-β inhibitory element; PEA-3,
Polyomavirus enhancer A-binding protein 3; SBE, STAT binding element; OSE-2, Osteoblast-specific element 2;
SPRE, Stromelysin-1 PDGF-responsive element. B. mRNAexpression of metalloproteinases mmp-1, mmp-13 and
mmp-3 under control conditions and after transient transfection with MEKK1∆ or Ha-rasmt was detected by semi-
quantitative RT-PCR. The products were separated on 2% agarose gels.
Next I tested the possibility that HPV-18 unresponsiveness could be due to a different composition
of the AP-1 after c-Jun induction and AP-1 binding reconstitution. This new composition can
alter theAP-1 function over the HPV regulatory region.Additionally the results presented in the
previous chapter indicated that in all cases were AP-1 binding was restored, Fra-1 expression
was also increased at mRNA and protein levels (Figures 30 panel B, 34, 35 and 41 panel B).
The increase of Fra-1 in the AP-1 complexes can lead to less trans-activator capability of AP-1
(Suzuki et al., 1991; Yoshioka et al., 1995) or can recruit a repressor that diminishes HPV-18
expression. However, this is not a general effect because other AP-1 driven promoters can be
induced (e.g. the metalloproteinases MMP-1 and MMP-3).
All this evidence prompted us to verify the negative role of Fra-1 in HPV-18 E6/E7 expression
in HeLa and HeLa RARβ clones.
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3.2.4 Role of Fra-1 as negative regulator of the HPV-18 expression
3.2.4.1 Antisense silencing of Fra-1 during AP-1 binding reconstitution by MEKK1∆
in HeLa RARβ clones
In the first approach to confirm the Fra-1 inhibitory effect over the HPV-18 promoter after
the AP-1 binding reconstitution, I used an antisense construct to try to silence Fra-1 expression
after the transient transfectionwithMEKK1∆. The aimwas to increase theAP-1 content, inducing
c-Jun, without concomitant incorporation of Fra-1 in the AP-1 complex.
The pCI-neo Fra-1 AS which carried the cDNA of fra-1 gene in antisense orientation under the
control of the human cytomegalovirus (CMV) promoter, was used in transient co-transfections
with MEKK1∆. The ratio of pCI-neo Fra-1 AS:MEKK1∆ was 3:1, to ensure that all cells that
receive MEKK1∆ have also incorporated the fra-1 antisense construct
The results are shown in the figure 49. The antisense did not work neither in HeLa nor in HeLa
RARβ clones and Fra-1 induction was not diminished after pCI-neo Fra-1AS transfection. The
Fra-1 induction and c-Jun phosphorylation revealed successful transfection, because MEKK1∆
induces both effects.
Figure 49 Fra-1 antisense and MEKK1∆ co-transfection in HeLa and HeLa RARβ clones. A. Western blot
analysis of 25µg of nuclear extracts from transient transfected cells. After electrotransfer, the blots were incubated
with phospho-c-Jun and Fra-1 antibodies. Equal loading was confirmed with an actin-specific antibody.B. HPV-18
expression after transfection was monitored by Northern blot.After transfer, the filter was hybridized with an HPV-
18 specific probe. RNA loading and transfer was monitored by hybridization with an actin probe.
Since the transient expression of Fra-1 antisense construct was unsuccessful, the next strategy
was the stable expression of fra-1 cDNA in HeLa cells using amphotropic retroviral vectors.
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3.2.4.2 Retroviral infection of HeLa cells to reach stable and constitutive
expression of Fra-1
In order to test if Fra-1 over-expression is enough to reduce HPV transcription, HeLa cells
were infected with retroviral vectors carrying the cDNA of fra-1 gene (Figure 50).
Figure 50Restriction analysis of the fra-1 retroviral plasmid.A. The Fra-1 cDNAwas cloned in theHpaI site (1479)
of the pLXIN vector. B. The orientation of the insert was determined by restriction analysis withApaI.
The sense and empty vectorswere used to transfect the packaging cell line PT67 (Figure 51).Twenty-
six and forty-eight hours post-transfection supernatants from the virus producing cellswere collected,
the virus containing medium was filtered and stored at 70°C.
Figure 51 Packaging cell line scheme.
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HeLa cells were infected with the virus-containing medium and after 24 hours, the cells
were selected in the presence of geneticin (G-418). After 7 days resistant clones were pooled
and RNA and nuclear extracts were prepared.
Figure 52 panel A shows the c-Jun and Fra-1 protein expression levels. After retroviral
infection Fra-1 was overexpressed while c-Jun was not altered. In the panel B, the Fra-1
incorporation in the AP-1 complex was analyzed. After PhosphorImager quantification an
increment of 10 fold in Fra-1 incorporation in the AP-1 complex was determined. However
in the panel C, a comparison in the HPV-18 expression between HeLa cells infected with
Fra-1 and HeLa cells infected with the empty vector shows that oncogene expression was
not reduced by Fra-1 over-expression in the HeLa cells.
Figure 52 Analysis of HeLa cells that constitutively express fra-1 gene. A. Immunoblot analysis of nuclear
extracts separated in SDS-10%polyacrilamide gel following by electrotransfer and incubationwith specific antibodies.
Equal loading and protein transfer was confirmed with an anti-actin antibody.B. EMSAsuper shift analysis of the c-
Jun, Fra-1 and c-Fos.Twomicrograms of nuclear extract wasmixedwith AP-1 binding oligonucleotide and incubated
30min at room temperature. Subsequently 1µg of the specific antibody was added following by a 60min incubation
at 4°C. C. HPV-18 expression was determined by Northern blot analysis. Five micrograms of RNAwas loaded in
1% agarose gel. After transfer the blot was hybridized with an HPV-18 specific probe. Transfer was controlled by
hybridization with an actin probe.
From the results I concluded that the increased incorporation of Fra-1 into the AP-1 complex
which is observed after constitutive and stable expression of the fra-1 cDNA is not sufficient to
reduce HPV-18 oncogene expression.
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IV. DISCUSSION
4.1 RARβ trans-repression of AP-1 transcription factor
4.1.1 RARβ trans-repression of AP-1 transcription factor
HeLa cells do not express detectable levels of RARβ both on RNA and protein level.
Nevertheless RARβ can be induced by pharmacological doses of retinoic acid without
alterations in the expression of RARα (Figure 16).
Stable transfection of HeLa cells with retinoic acid receptor β leads to a constitutive
expression of the nuclear receptor (Figure 16) which result in a slower growth rate in
comparison with HeLa parental cells (Figure 39). The expression of RARα was not alter by
transgene expression. RARβ was functional as shown by RARE-Luciferase expression
experiments (Figure 17).
In order to analyze the effect of constitutive RARβ expression on AP-1 activity, its amount
in HeLa RARβ clones was determined. The results of the figure 18 showed that AP-1 is
highly reduced, reaching only between 20-30% of the HeLa parental cells AP-1 content.
The RARβ-mediatedAP-1 trans-repression has been well documented in other cancer models
(Chen et al., 1995; Yang et al., 1997; Li et al., 1999; Li et al, 1998a; Li et al., 1998b; Wu et
al., 2002).
In the case of HeLa parental cells treated with atRA, theAP-1 content is approximately 40%
of the HeLa untreated cells (Figure 18). However is important to note that retinoic acid
treatment of HeLa cells induces RARβ expression and simultaneously also activates all
retinoic acid receptors. Hence, the AP-1 effect after retinoic acid treatment might be due to
more than one mechanism. In contrast in the RARβ clones, AP-1 reduction appears to be
mainly due to the RARβ constitutive expression.
As in other cancer models in HeLa cells AP-1 trans-repression by retinoic acid receptor β
acts and might be a mechanism to control cell proliferation.
4.1.2 Mechanism of AP-1 down regulation
The mechanistic basis of the anti-AP-1 activity by retinoic acid receptors has remained
elusive and the role of the specific retinoic acid receptors isotypes (α, β, γ) or the accessory
protein interactions has not been addressed (Altucci and Gronemeyer, 2001). Some of the
hypotheses tested to date to explain RARs/AP-1 trans-repression will be briefly described
below (Figure 53).
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Figure 53: Several mechanisms, which need not be mutually exclusive, may account for the RARs/AP-
1 trans-repression. a). Direct o indirect interaction that generate abortive DNA complexes. b). Competition
for limiting amounts of a common co-activator (Co-A), such as CBP o p300. c). Inhibition of Jun amino
terminal kinase (JNK) signalling pathway which prevent c-Jun activation. d). Jun-Fos dimerization disruption
by ligand-activated RARs.
i. Competition for a common coactivator: Competition for limiting amount of the
coactivators between liganded RARs andAP-1. The competition results in the activation
of only one pathway (Kamei et al., 1996).
ii. Blockage in the dimerization: interference between liganded RARs and Jun/Jun
homodimerization and Jun/Fos heterodimerization, preventing the formation of AP-1
complexes. This effect can be direct or involve an unknown intermediate factor (Zhou et
al., 1999).
iii. Down-regulation of c-Fos expression and/or activity: transcriptional interference of the
nuclear receptors with the serum response element in the promoter of c-fos, inhibits its
expression leading toAP-1 reduced activity.Additionally, it has been reported that retinoids
inhibit the transcriptional trans-activation of c-fos (Talmage and Listerud, 1994; Perez et
al., 1994).
iv. Induction of Fra-1 expression: since Fra-1 lacks a trans-activation function, the retinoid
mediated induction of fra-1might function as a negative regulator ofAP-1 activity (Kai-
ser et al., 1999).
v. Direct or third protein-mediated binding between c-Jun and RARs or c-Fos and RARs leads
to sequestration of the AP-1 complexes and titrate them out. However, the interaction ap-
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pears to be weak because the complexes can not be detected in the absence of chemical
cross-linking agents. Additionally, the RAR binding can generate an unproductive com-
plex RAR/AP-1 at the TRE sequence that eventually can induce DNAbends, association
with co-repressors or conformational changes in the AP-1 dimer reducing its trans-acti-
vation potential (Schüle et al., 1991; Pfahl, 1993; Schroen and Brinckerhoff, 1996).
vi. Direct or indirect inhibition of Jun N-terminal kinase activation in the cytoplasm, the
direct inhibition could be possible due to an interaction between the nuclear receptor and
the enzyme or could interact through intermediate proteins in the frame of multi-protein
complexes where JNK may be associated. There also remains the possibility that some
up stream component is the primary target of the activated nuclear receptor and not the
JNK itself, being the consequence the lack of JNK activation (Gonzalez et al., 1999;
Gonzalez et al., 2000).Additionally, it has been postulated that the JNK inhibition can be
mediated by the retinoic acid transcriptional induction of a phosphatase responsible for
the JNK dephosphorylation and inactivation. One candidate is theMAPK phosphatase 1,
MKP-1, which increased in abundance with retinoic acid treatment. The JNK inhibition
consequently prevents c-Jun phosphorylation resulting in a negative regulation of c-Jun
transcriptional activity and c-junmRNA expression and increases the c-Jun protein deg-
radation (Lee et al., 1999).
vii. Inhibition of c-Jun protein induction: this event can occurs either through inhibition of c-
Jun translation and/or accelerated degradation of c-Jun. Is postulated that retinoic acid
treatment might stimulate c-Jun dephosphorylation promoting its degradation but the
inhibition of c-Jun protein induction requires prolonged pre-treatment with retinoic acid
(Fisher et al., 1998). On the other hand, it has been suggested that retinoic acid mediates
the activation of the glycogen synthase kinase 3, which potentially could inhibit AP-1
activity through c-Jun C-terminal phosphorylation, impairing the DNA binding of the
AP-1 complexes. Moreover, for other transcription factors phosphorylation by GSK-3
can lead to targeting to the proteasome for degradation (Benkoussa et al., 2002).
In order to clarify themechanismbywhichAP-1 trans-repression is achieved inHeLa cervical cancer
cells, the most relevantAP-1 family members were analyzed at RNAand protein levels (Figure 19).
It is remarkable that c-Jun protein was almost undetectable in the RARβ clones, nevertheless c-jun
mRNA was present. These results are according to the hypothesis vii above, although the sole
overexpressionof theRARβwithout a pre-treatmentwith all-trans-retinoic acid, is enough to induced
the c-Jun degradation.
Interestingly, the c-Jun reduction is not that strong in the HeLa cells after 3 days of retinoic acid
treatment.This could be explained because the atRAtreatment can activated all nuclear receptors and
probably more than one mechanism is involved in theAP-1 trans-repression under such conditions.
The way by which retinoic acid affects theAP-1 pathways may vary from cell type to cell type. For
example, retinoicacid inhibits c-junandc-fosexpression in synovial fibroblasts.Conversely in vascular
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smooth muscle cells, retinoic acid inhibits AP-1 activity without suppressing expression of c-
jun and c-fos. In human bronchial epithelial cells retinoic acid treatment inhibits the growth
factor-induced activation of JNKwhile in human skin, retinoic acid inhibits ultraviolet-triggered
accumulation of c-Jun via a post-transcriptional mechanism without affecting the JNK pathway
(Moreno-Manzano et al., 1999; Fisher et al., 1998).
It has been suggested that themechanism ofAP-1 trans-repression byRARs can be cell-dependent
and/or stimuli-dependent. Likewise, in some cases more than one mechanism can be presented
simultaneously (Moreno-Manzano et al., 1999).
In the case of HeLa RARβ clones is possible to dissect the mechanism by which RARβ influences
AP-1. In these cells, RARβ-mediated post-transcriptional degradation of c-Jun is mainly
responsable for the AP-1 down-regulation. Nevertheless the presence of other mechanisms can
not be ruled out.
4.1.2.1 Mechanism of c-Jun down regulation
The post-transcriptional degradation of c-Jun could bemediated by alterations in the activity
of different proteins responsible for its stabilization or de-stabilization.As was discussed before
JNK, MKP-1 and GSK-3, can be involved in the c-Jun degradation either direct or indirectly. In
the figure 22 it is possible to compare the expression and activation of these molecules in HeLa
and HeLa RARβ clones under control and stimulated conditions. No differences can be observed
between HeLa and the RARβ clones. JNK activation is stronger in the clones than in HeLa
parental cells. MKP-1 expression is not affected by the constitutive expression of the RARβ and
the active GSK-3 is comparable between all cell lines with or without stimulation.
JNK has been postulated as the main regulator of the c-Jun stability (Fuchs et al., 1996; Musti et
al., 1997; Buschmann et al., 2000). However my results indicate that c-Jun post-transcriptional
down-regulation in the HeLa RARβ clones is JNK independent and JNK activation was not
impaired by the over-expression of RARβ even after its activation by atRA treatment (section
3.1.3). The results show that RARβ receptor per se is unable to impair the activation of JNK by
any stimuli tested. The possible explanation for this is that themechanism bywhich atRAinhibits
JNK induction is not mediated by RARβ.Additionally, it may be that JNK inhibition by retinoic
acid receptor β is stimulus- and cell-type-dependent (Lee et al., 1999).
4.1.2.2 Increase of c-Jun protein leads to AP-1/DNA-binding reconstitution in HeLa
RARβ clones
AP-1/DNA-binding reconstitution not always implies c-Jun accumulation to the HeLa
parental cells levels. Strong and transient stimuli (such as TNFα) as well as constitutive weak
stimuli (such as Ha-rasmt transfection) of the JNK showed AP-1 binding reconstitution in the
absence of detectable amount of c-Jun by Western blot. This disparity is maybe produced by a
transient phosphorylation of c-Jun, which is preferentially incorporated in the AP-1 complex
without accumulation of the protein (Figures 25 and 34). In the other hand, strong and sustained
stimuli result in c-Jun protein accumulation as well as AP-1 DNA binding restoration (Figures
27, 30 and 34). Then different stimuli can differentially affect the c-Jun content in HeLa
RARβ clones. Transient signals lead to c-Jun degradation but sustained JNK activation (by
MG-132, serum stimulation orMEKK1∆) allows the phosphorylation of more c-Jun molecules.
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The phosphorylation of c-Jun increases the expression of c-jun mRNA (by an auto-regulatory
loop, Steinmuller et al., 2001), this then increases the synthesis of c-Jun protein, which can be
stabilized by the phosphorylation of the active JNK. This process is not affected by the RARβ
expression.
Consequently, it is possible distinguish between theRARβ function in resting and stimulated cells. In
resting cells constitutive expression of RARβ leads to an increase of the proteasomal degradation of
c-Jun. Possibly RARβ increases degradation of proteins, including c-Jun, by modification or de-
regulation of regulatory subunits in the proteasome complex (Boyle, 2001).
Alternatively,RARβmaybe less effective in stimulated cells because the sustained activation of JNK
and c-Jun phosphorylation can generate a bulk of more stable c-Jun protein. This in addition to the
higher rate of c-junmRNA synthesis allow the c-Jun accumulation.
The down regulation of c-Jun is a post-translational phenomenon that involve a proteasomal
degradation of the unstable unphosphorylate proteins. The JNK activation is not the target
for the RARβ driven labilization of c-Jun because it is possible activate this kinase by all
stimuli tested in the presence of RARβ receptor unbound or bound to retinoic acid. After
JNK activation, c-Jun becomes phosphorylated and this stabilizes the protein by inhibiting
the degradation. All non-phophorylated protein is degraded. Only when a pool of stable
proteins is reached the c-jun gene is induced and more c-Jun protein is generated. Under
strong and sustain stimulation c-Jun is continuously phosphorylated, and by a feedback
mechanism c-Jun is accumulated (model 1).
Model 1:Workingmodel to explain c-Jun response in HeLaRARβ clones in function of JNK signal duration.
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4.1.3 Role of RARβ on protein degradation
The mechanisms by which retinoids might modulate ubiquitin-dependent proteolysis are
unknown. It is possible that RARs might directly trans-activate ubiquitin activating enzyme E1,
ubiquitin conjugating enzyme E2 and/or ubiquitin ligase E3 (recognizing specific substrates).
Conversely, RARs may disrupt other control mechanisms (Boyle, 2001).
It has been described that retinoic acid can alter the degradation rate of some cell cycle proteins
leading to down-regulation of cyclinsA, B, D1 and E, CDK-2, CDK-4, CDK-6 and up-regulation
of p21 and p27 (Dimberg et al., 2002). The analysis of some of these proteins (Figure 38) showed
that in the HeLa RARβ clones only cyclin D1 was affected while p53, p27 and p21 were up
regulated.
Cyclin D1 is regulated at transcriptional and post-transcriptional levels (Spinella et al., 1999).
The human Cyclin D1 gene contains twoAP-1 binding sites and c-Jun has been found to induce
transcription of Cyclin D1 in transient transfection assays (Shaulian and Karin, 2001). Since
HeLa RARβ clones contains significantly less c-Jun and less AP-1 than the parental cells, it is
possible that the lower levels of Cyclin D1 are consequence to lower mRNA synthesis. In human
bronchial cells treated with retinoic acid, Cyclin D1 degradation depends on the proteasome-
ubiquitination pathway. Use of a retinoid receptor selective agonist demonstrated that RARβ
receptor but not RARα or RARγ dependent pathways signaled this cyclin degradation (Dragnev
et al., 2001; Boyle et al., 1999). Based on the results from theWestern blot it was not possible to
clarify which of these mechanisms were presented in the HeLa RARβ clones.
The up regulation of p53 (a negative growth regulator), could correlate with a reduction in HPV-
18 E6 expression (Scheffner et al., 1990; Werness et al., 1990; Huibregste et al., 1993) and the
absence of c-Jun in the HeLaRARβ clones. It has been described that c-Jun is a negative regulator
of both p53 expression and its ability to activate target gene transcription (Shaulian and Karin,
2001). The up regulation of p21 can be partially explained by the p53 up regulation, as p53 is a
transcription factor required for p21 expression (Shaulian and Karin, 2001). Additionally it was
shown that in the absence of added retinoid, RARβ over-expression in neuroblastoma cells in
vitro leads to induction of p21 expression mediated by a RARE sequence located in the promoter
region of the p21 gene (Cheung et al., 1998; Dimberg et al., 2002).
p27 up regulation has also been associated with RARβ over-expression in lung cancer cells
(Hsu et al., 2000) but the mechanism is still unclear being postulated a post-transcriptional
protein stabilization without transcriptional modulation (Dimberg et al., 2002). This observation
suggests a RARβ compromise in the proteasomal regulation.
It can be concluded that the modulation of cell cycle inhibitors, Cyclin D1 and p53 in addition
to the AP-1 trans-repression and HPV-18 oncogenes down-regulation (Figure 42) may explain
the reduced growth of the HeLa RARβ clones.
4.1.4 Role of POH1 in c-Jun stabilization in HeLa RARβ clones
The analysis of proteasome regulatory proteins involved in c-Jun stability and degradation is
difficult due to the fact that many proteasome regulatory sub-units are unknown and in most
cases is not clear how the selectivity and specificity of proteasome degradation is conferred.
Nevertheless, I analyzed the POH1 protein, a proteasome regulator sub-unit that can confer
stability to c-Jun protein (Spataro et al., 1997; Nabhan et al., 2001). RARβ did not affect POH1
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mRNA or protein expression (Figure 40) although is still possible that RARβ over-expression can
somehow impair POH1 activity. Transient transfection with POH1 expression vector led to
incorporation of c-Jun in the AP-1 complex as detected by EMSA supershift. This was a specific
effect as Oct-1 binding activity was not affected (Figure 41 panel A). Although c-Jun protein
accumulationwas not detected byWestern blot increased expression of Fra-1 indicated functionality
(Figure 41panelB).The results suggest that the inhibitory capability of theRARβ could be overcome
by POH1 transient transfection. POH1 over-expression probably stabilizes some c-Jun molecules
increasing strongly their incorporation in theAP-1 complex. In fact is possible that stable transfection
ofPOH1andconstitutivepoh1geneexpressionwill lead toahigher stabilizationof thec-Junmolecules.
Alternatively, several proteasome regulator molecules might be involved.
Recently a ubiquitin ligase enzyme huCOP1 (Human constitutive photomorphogenesis protein 1)
which interacts specificallywith c-Jun protein has been described. COP1may function as a ubiquitin
ligase that directly targets transcription factors fordegradation, raising thepossibility that ubiquitination
of c-Jun by huCOP1 may occur (Bianchi et al., 2003). Another constitutive photomorphogenesis
protein COP9, has been described as modulator of the c-Jun activity. COP9 increased c-Jun protein
content leading to elevatedAP-1 transcriptional activity (Naumann et al., 1999). Imbalance between
these activities could result in c-Jun reduction. Is unknown if the COP proteins are related with the
RARβ signalization but dys-regulation of this regulatory proteins may be involve in the c-Jun
degradation.
Based on the results presented in the chapter 4.1 it was possible to determine that the labilization of
c-Jun protein is driven byRARβ receptor specifically. Themechanisms bywhich atRA throughRARβ
exerts its AP-1 repression in HeLa cervical cancer cells is not the same postulated in other cancer
cellsmodels (Perez et al., 1994;Kamei et al., 1996; Schroen andBrinckerhoff, 1996; Lee et al., 1999;
Zhou et al., 1999; Suzukawa and Colburn, 2002). The results showed that RARβ induced degrada-
tion of c-Jun protein, resulting in AP-1 reduction. JNK function is not impaired. The RARβ receptor
effect is reversible and under strong and sustained stimulus c-Jun protein is accumulated and AP-1-
DNA binding is restored.
4.2 Effect of RARβ expression on HPV-18 oncogenes E6/E7
4.2.1AP-1 binding reconstitution and HPV-18 expression
Constitutive HPV-18 E6/E7 down-regulation (Figures 42 and 43) correlates with AP-1 trans-
repression in HeLa cells treated for 3 days with atRA and in the HeLa RARβ clones under control
conditions (Figures 18 and 45 panelA).This is consistent with previous reports about the importance
ofAP-1 transcription factor in HPV-18 oncogene expression (Butz and Hoppe-Seyler, 1993).
The evidence suggest that themechanism bywhich retinoic acid negatively regulates HPV-18 E6/E7
expression rely in the AP-1 trans-repression by retinoic acid receptors. Furthermore, in the specific
case of the HeLa RARβ clones the results indicate that the mechanism by which retinoic acid
receptor β down regulate the oncogene expression is the AP-1 transcription factor reduction
due to increased c-Jun degradation.
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In contrast with the above results, reconstitution of AP-1 binding failed to up regulate HPV-
18 oncogenes E6/E7 expression. For some of the treatments employed in this work the
HPV-18 unresponsiveness was not surprising (Figure 46). For example in the case of
proteasome inhibitor MG-132 the effect over the cells is highly unspecific and it is possible
that inhibitors of HPV-18 expression accumulate with similar kinetics as c-Jun.
Nevertheless specifically in the case of Ha-rasmt over-expression, the result was unexpected.
It has been reported that HeLa cells stably transfected with Ha-rasmt exhibit up regulation of
HPV-18 expression due to c-Jun/c-Fos induction/activation (Medina-Martinez et al., 1997).
Ha-rasmt transfection activates the extracellular signal-regulated kinase (ERK) pathway
resulting in c-Fos induction at RNA and protein levels. The c-Fos increment would lead
preferentially in c-Fos/c-Jun heterodimers, which are more stable than c-Jun/c-Jun
homodimers (Ryseck and Bravo, 1991). The reconstituted AP-1 would mainly content c-
Fos/c-Jun complexes and consequently up regulate the HPV-18 expression. In the present
work in contrast to the expectations Ha-rasmt transfection did not induce c-Fos expression
either at RNA level (Figure 34 panel A) nor at protein level (Figure 35).
One explanation for this disparity is that stable transfectants get cellular modifications that
do not occur in transient transfection experiments. Alternatively, c-Fos transcription via
Ras/ERK activation might be inhibited. In my Ha-rasmt analysis I found c-Jun and Fra-1 up
regulation but an unexpected c-Fos down regulation (Figure 35). The explanation for this
observation might be the ability of c-Fos and Fra-1 to down-regulate the c-fos promoter. c-
Jun up regulation via Ras allows its heterodimerization with c-Fos and Fra-1 but only maintain
an elevated level of Fra-1 synthesis due to c-fos promoter inhibition. Consequently, in
response to Ras-signals the accumulation of Fra-1 is predominant over c-Fos and more c-
Jun/Fra-1 complexes will be generated (Figure 54, for review, see Tulchinsky, 2000). This
phenomenon was observed in HeLa and HeLa RARβ clones and may explain why AP-1
composition was predominantly c-Jun/c-Jun and c-Jun/Fra-1 in the present work in contrast
to c-Jun/c-Fos reported by Medina-Martinez et al., 1997.
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Figure 54: c-Fos negative feedback after Ras stimulation of ERK and JNK pathways
Additionally, the AP-1 differences must account for the differential HPV-18 expression in the
both studies, being up regulated when theAP-1 is predominantly c-Jun/c-Fos (Medina-Martinez
et al., 1997) and kept down regulated whenAP-1 is predominantly c-Jun/c-Jun and c-Jun/Fra-1
(present study).
From the analysis of metalloproteinase gene expression (Figure 48) it is possible to group the
AP-1 driven genes in the HeLa RARβ clones in four classes: the non-expressed genes under
control conditions that can be up regulated after AP-1 induction (MMP-1 and MMP-3); the
genes expressed under control conditions that can be up regulated after AP-1 reconstitution
(Fra-1); the genes expressed under control conditions that are not affected after AP-1 elevation
(MMP-13) and finally the genes that are down regulated under control conditions and can not be
re-induced after AP-1 restoration (HPV-18 E6/E7 oncogenes).
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It is described for collagenase 3, (MMP-13) that the dimer c-Jun/Fra-1 regulates its
constitutive expression. (Selvamurugan and Patridge, 2000). However for the induction of
this gene, an AP-1 composition c-Jun/c-Fos is required. As is shown in the figure 48, the
mmp-13 gene was constitutively expressed under conditions in which c-Fos incorporation
in the AP-1 complex was relatively low and the AP-1 composition is predominantly c-Jun/
c-Jun and c-Jun/Fra-1 (section 3.1.2.1 and figure 35). On the other hand, the collagenase 1,
(MMP-1) promoter is activated and induced by c-Jun/c-Jun homodimers (Westermarck and
Kähäri, 1999) as is shown in the figure 48.
The individual Jun and Fos family members exhibit different binding affinities for the AP-
1 sites in the MMP promoters (Benbow and Brinckerhoff, 1997).
This observation is according to the demonstration that the composition of AP-1 and the
promoter environment (different elements surroundingAP-1 binding site) play a role respect
to the differential gene expression (Angel et al., 2001; van Dam and Castellazzi, 2001;
figure 55).
AP-1 exhibit differential effects although the same preferential dimer formation (c-Jun/c-
Jun, c-Jun/Fra-1). It was possible to detect a c-Jun, Fra-1, MMP-1 and MMP-3 gene induction
after AP-1 reconstitution but no HPV-18 oncogene or MMP-13 up-regulation.
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Figure 55 Differences in AP-1 composition and promoter environment regulates positively or negatively
different set of genes.
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Furthermore, it has been shown that a particularAP-1 composition mediates negative regulation
of HPV transcription. Treatment of HPV-16 immortalized human keratinocytes with the antioxi-
dant pyrrolidine-dithiocarbamate (PDTC) selectively reduced the amount of viral mRNA at the
level of initiation of transcription. Suppression was accompanied with an enhanced affinity of
AP-1 to its cognate binding site within the URR and a preferential association of c-Jun and JunB
with Fra-1 instead c-Fos. The suppression of HPV-18 and the higher binding of the AP-1 to the
URR were also observed after AP-1 elevation (Figures 46 and 47). The higher incorporation of
Fra-1 in theAP-1 complex is shown in figure 35. Elevated levels of Fra-1 compete out the trans-
activation of AP-1 prototype c-Jun/c-Fos-complexes onAP-1 responsive marker genes (Suzuki
et al., 1991; Yoshioka et al., 1995), it was reasonable to assume that viral suppression was
mainly due to the reorganization ofAP-1 transcription complexes in PDTC treated cells (Rösl et
al., 1997) as well as in HeLa RARβ stably transfected clones. In fact it has been demonstrated
that AP-1 acts not only as a positive regulator as previously thought, but also functions as a
central key element in an intracellular surveillance mechanism negatively controlling HPV tran-
scription and tumorigenicity (Soto et al., 1999).
Moreover, heterodimerization with Fra-1 involved the abrogation ofAP-1 activity under certain
conditions (Yoshioka et al., 1995). Fra-1 was substantially increased within the AP-1 complex
of non-malignant cells and diminished or absent in the malignant counterparts. This suggest that
the concentration of Fra-1 within theAP-1 transcription complex might be an important marker
to predict in vivo growth properties of HPV-positive cells (Soto et al., 2000).
Recently it has been published new evidence of the negative role of the Fra-1 composed AP-1
over the HPV-18 expression. The expression of activated Notch-1 transcription factor in HPV
positive cells lead to c-Fos suppression and Fra-1 induction and incorporation in theAP-1 complex.
This changes in the intracellular balance of individual AP-1 components result in HPV-18 E6/
E7 transcriptional down regulation (Talora et al., 2002).
It is possible to suggest that AP-1 composition after its elevation in HeLa RARβ clones, which is
mainly c-Jun/c-Jun and c-Jun/Fra-1, negatively regulates the expression of HPV-18 keeping
down the oncogene expression.
4.2.2 Role of Fra-1 as negative regulator of the HPV-18 expression
4.2.2.1 Retroviral infection of HeLa cells to reach stable and constitutive
expression of Fra-1
The Fra-1 overexpression in HeLa cells did not modify HPV-18 E6/E7 oncogene expression
(Figure 52 panel C). However, is important to notice (Figure 52 panel A) that Fra-1 protein
accumulated after HeLa retroviral infection has a faster migration than the protein accumulated
by the other treatments (Figures 30, 34, 41, 49). It is possible that phosphorylation may be
important in the negative down regulation of HPV-18 or, that phosphorylation can result in
recruitment of a thirdmolecule that inhibits HPV-18 expression (Hurd et al., 2002).Alternatively,
a third molecule could be expressed, activated or bound to Fra-1/AP-1, only under cell stimulated
conditions (Philips et al., 1998; Piu et al., 2001).
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It has been shown that tumor cells possess higher phosphatase activity than non- tumori-
genic cells. It is possible that this phosphatase activity de-phosphorylates Fra-1 in the HeLa
cells stably expressing Fra-1 (only detectable fast migrating forms), leading to an unchanged
expression of HPV-18 oncogenes. The inhibition of this phosphatase by stimulated trans-
duction pathways could lead to the Fra-1 phosphorylation (slow migrating forms are de-
tected) which result in the direct or indirect HPV-18 oncogenes down-regulation.
Alternatively, may be important the content of c-Jun in order to allow the formation of c-
Jun/Fra-1 complexes. Might be that the up-regulation of Fra-1 did not result in the HPV-18
down regulation because c-Jun, the dimerization partner which is responsible for DNA bind-
ing, is not present in enough quantity.
Stable and constitutive Fra-1 overexpression is not sufficient to down regulate HPV-18 and
additional modifications of Fra-1 specifically, or AP-1 in general, must be necessary to
reduce the oncogene expression.
In conclusion, the complexity and plasticity of the AP-1 transcription factor can not be
simplify only by the accumulation of the subunits or the composition of the complex at any
given time. Additional effects such as post-translational modifications of the specific sub-
units or interaction with other proteins during the building of the transcriptional complex
can determine the effect of the AP-1 on specific promoter regions given differential re-
sponses and these hypothesis open new research perspectives on the AP-1 function and
regulation.
The AP-1 down-regulation by retinoic acid receptor beta in HeLa HPV-18 positive cells has
consequences at the oncogene expression level but interestingly the re-induction of the HPV-
18 expression in HeLa RARβ clones is not easily achieved. This could be a promising ad-
vantage in the case of RARβ-based cervical cancer therapy because all changes produced
in HeLa RARβ clones after the retinoic acid receptor beta constitutive expression lead to
growth arrest and tumor growth suppression.
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V. ABSTRACT
The nuclear retinoic acid receptor β2 (RARβ2) gene is epigenetically modified and unable to
be significantly induced in many types of cancer, including cervical cancer. RARβ2 can act as a
tumor suppressor, since loss of its expression is associated with human tumor progression. One
mechanism of RARβ2-mediated growth inhibition is based on its ability to constitutively repress
theAP-1 transcription factor, but this mechanism has never been demonstrated in cervical cancer
cells.
In this thesis the biological consequences of reconstitute RARβ2 receptor expression in cervical
cancer cells was investigated. For this purpose, human papillomavirus HPV-18 positive HeLa
cells were stably transfected with RARβ2 cDNAunder the control of the β-actin promoter. The
characterization of the RARβ2 tranfectants revealed a strongly reduced AP-1 binding to the
corresponding specific oligonucleotides, even in the absence of all-trans-retinoic acid treatment.
In HeLa cells, the AP-1 reduction correlates with diminished HPV-18 oncogene transcription
and slower cellular growth.Western blot analysis demonstrated that the only member of theAP-
1 family consistently reduced inHeLaRARβ2 cloneswas c-Jun, despite ongoing gene expression.
In order to understand the mechanism by which c-Jun is reduced, and since the phosphorylation
of c-Jun is important for protein stabilization, HeLa RARβ2 clones were treated with different
c-Jun-N-terminal kinase stimulators. These treatments resulted in a c-Jun increase at RNA and
protein levels, and led to a reconstitution ofAP-1 binding similar to non-transfectedHeLa controls.
However, the reconstitution of AP-1 binding levels did not have an inductor effect on the HPV-
18 oncogenes, the expression of which has been postulated to beAP-1 dependent. Other classical
AP-1 regulated genes such as metalloproteinases were up regulated as expected.
In conclusion, the data of this thesis indicate that RARβ2 induced a destabilization and degradation
of c-Jun protein, which causes AP-1 reduction. The mechanism of AP-1 trans-repression by
RARβ2 in HeLa cells is different from that postulated for other cell systems. RARβ2 constitutive
expression lead to reduced cell proliferation of HeLa cells, which can be associated with the
RARβ2 tumor suppressor function.
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